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ABSTRACT 
ROLES OF 5HT1A RECEPTOR IN CNS NEUROGENESIS 
AND ADAM21 IN SPINAL CORD INJURY 
Sheila Ann Arnold 
July 21, 2011 
These studies set out to identify strategies to rescue and repair the adult nervous 
system. First, we investigated the role of ciliary neurotrophic factor (CNTF) in SHT1A 
receptor-induced neurogenesis in the rodent brain. Systemic treatment with an agonist, 
8-0H-DPAT, increased neurogenesis only in rats and not mice, and only in one of the 
two neurogenic regions. This increase was not mediated by CNTF. These data suggest 
that translation of SHT1A-based studies to human cell replacement therapies should be 
reconsidered. Secondly, the role of the plasticity-associated metalloprotease ADAM21 
after spinal cord injury was investigated by comparing ADAM21-deficient mice to their 
wildtype littermates. No differences in behavioral or histology were found. However, a 
comprehensive metalloproteinase gene array revealed that ADAM21 regulates a cluster 
of inflammatory genes following injury. This leaves a potential for discovery of specific 
pharmaceutical ADAM21 inhibitors to reduce detrimental inflammatory processes 
following spinal cord injury. 
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Plasticity persist in the adult brain, mainly in two distinct regions known as the 
subventricular zone (SVZ) and the subgranular zone (SGZ). With the discovery of 
neural stem cells in the adult brain, the concept of neuronal replacement via engraftment 
of these cells into the damaged region has sparked excitement. However, in light of 
problems faced with engraftment (tumor growth, misguidance, cell death, cognitive 
impairment, and lack of sufficient functional recovery), many scientists have refocused 
their attention to neuroprotection in order to prevent the initial loss of neurons and 
regeneration using the endogenous cells to alter the neurogenic potential. The focus for 
regeneration in many neurodegenerative diseases stem from the idea that the newly 
born neurons in the SVZ and SGZ could replace the lost neuronal population under the 
correct conditions or in a special environment. Aside from prevention of the initial injury 
in spinal cord injury, there is a small window of opportunity for limited neuroprotection of 
the neurons that were spared in the initial injury. Secondary injury, which is caused by 
inflammation in response to the initial injury, causes further damage that could 
potentially be prevented thus neuroprotective. However, plasticity also occurs following 
spinal cord injury that could have the potential to either cause regeneration of the 
damaged or restore function to lost/damaged axons or it can cause increases in pain 
perception. This introduction will review topics about CNS neurogenesis, 
neurodegenerative diseases, the possible link between 5HT1A receptor induced 
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neurogenesis and CNTF. Additionally, there will be a brief introduction to spinal cord 
injury, the Metzincin superfamily, matrix metalloproteinases, ADAMs and the possible 








~cAMP ¢ ~CNTF¢ Neurogenesis 
Neurogenesis 
The thought that the brain is malleable or able to change is a relatively modern 
idea. Though proposed in 1890 by William James in The Principles of Psychology, proof 
of neurogenesis was not shown until Smart in 1961 found new neurons in the 
subependymal layer of mice. Altman and Das similarly found new neurons in the 
hippocampus of rats and showed dividing cells of not only glial origin but also 
proliferation of new neurons which continued throughout life in post-natal mammals 
refuting the dogma that neurogenesis ceased upon maturation (Smart, 1961, Altman and 
Das, 1965). Although these two papers are most commonly cited as being the first to 
discover neurogenesis in the adult brain, Smart references papers written by Opalski in 
1934 and Kuhlenbeck in 1944 as referring to "the subependymal cell plate ... a potential 
source of undifferentiated cells which may on occasion give rise to neoplasms." 
However, the idea of adult neurogenesis was still controversial even after other 
laboratories had replicated this phenomenon (Hinds, 1968b, a, Kaplan and Hinds, 1977). 
Eventually, it became accepted that new neurons are continually added to the brain 
circuitry throughout life. Neurogenesis in the adult mammalian brain is now widely 
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known to occur in two distinct and unique regions of the brain-the lateral wall of the 
ventricles, known as the subventricular zone (SVZ), and in the sub granular zone (SVZ) 
of the dente gyrus in the hippocampal formation (Smart, 1961, Altman and Das, 1966, 
Altman, 1969, Lois and Alvarez-Buylla, 1994, Eriksson et aI., 1998, Goldman, 1998, 
Gage, 2000, Alvarez-Buylla and Lim, 2004, Hoglinger et aI., 2004, Lie et aI., 2004, Sanai 
et aI., 2004, Ming and Song, 2005, Hagg, 2009, Kriegstein and Alvarez-Buylla, 2009, 
Suh et aI., 2009, Ma et aI., 2010, Soumier et aI., 2010). In non-human primates, 
neurogenesis in the SGZ of the hippocampal formation of marmoset monkeys was found 
to be decreased with stress as was shown in other animals like the tree shrew and rat 
(Gould et aI., 1997, Gould et aI., 1998). Although neurogenesis was found in the SVZ 
and SGZ in some animals, the absence of neurogenesis in the adult human was still 
central dogma until relatively recent years. Now it is known that neurogenesis does 
occur in humans as was shown in the postmortem hippocampal formation of the brain in 
adult human cancer patients that received BrdU as a way to track the proliferation rate of 
their cancer (Eriksson et aI., 1998). However, there are conflicting reports of the 
presence or lack thereof of a rostral migratory stream in humans (Bedard and Parent, 
2004, Sanai et aI., 2004, Curtis et aI., 2007b, Sanai et aI., 2007). 
In the SVZ, there has been controversy over what cell type is the neural stem 
cell. A report published in 1999 indicated that ependymal cells were responsible for the 
generation of new neurons which migrate to the olfactory bulb (Johansson et aI., 1999). 
However, shortly thereafter, a study was published showing data in support of type B 
cells (SVZ astrocytes) and not ependymal cells are the cell type of origin of the neural 
stem cells in the SVZ (Doetsch et aI., 1999). These type B cells give rise to both type A 
(migrating neuroblasts) and type C (precursor cells). The concept of the SVZ astrocytes 
is the more widely accepted explanation for the origin of the neural stem cells in the 
SVZ; however, this controversy has yet to be fully resolved since there is a possibility 
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that these two populations in question are one and the same (Chojnacki et aI., 2009). 
Likewise, in the hippocampal formation there are type 1 and type 2 which are similar to 
the type B and type C cell, respectively, in the SVZ (Zhao et aI., 2008, Suh et aI., 2009). 
Both type B and type 1 cells resemble radial glial cells found in development. The 
finding that astrocytes are the neural stem cells responsible for the neurogenesis in the 
SVZ and SGZ means that in cases of neurodegenerative diseases, the astrocytes which 
are spared can possibly be exploited in order to replace neurons that are being lost. 
In rodents, the majority of adult neurogenesis occurs in the SVZ at a rate of 
approximately 10 times more than in the SGZ (Lois and Alvarez-Buylla, 1994, Cameron 
and Mckay, 2001, Winner et aI., 2002, Rao and Shetty, 2004, Abrous et aI., 2005). The 
newly born neuroblasts migrate from the SVZ along the rostral migratory stream to the 
olfactory bulb (OB) and from the SGZ into the neighboring granule cell layer, 
respectively, where they either become integrated as neurons or die (Cameron et aI., 
1993, Luskin, 1993, Lois and Alvarez-Buylla, 1994, Morshead et aI., 1998, Gould et aI., 
1999, Hastings and Gould, 1999, Dayer et aI., 2003). The new neurons from the SVZ 
migrate to the olfactory bulb become 90% GABAergic and 10% dopaminergic neurons 
while the new neurons in the SGZ become excitatory glutamatergic granule neurons 
(Knobloch and Jessberger, 2011). 
Neurodegenerative diseases 
Neurogenesis creates and sustains hope for people who have 
neurodegenerative diseases such as Huntington's disease, Parkinson's disease, ALS, 
etc. Although these diseases are different in their origination/development, they all 
share a common characteristic-loss of neurons. The neuronal population that is lost is 
different in these diseases. If the endogenous neurogenesis can be directed or focus on 
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replenishment of neurons lost over the progression of the disease then maybe we can 
attenuate the progression or quite possibly find a treatment/cure for these diseases. 
However, first the biology of neurogenesis and its endogenous regulation must first be 
explored before we can pharmacologically manipulate it in various disease states as 
opposed to engraftment of neural stem cells. Pharmaceutical intervention has less 
ethical and safety hurdles to overcome before it can be utilized in neurodegenerative 
diseases. There is a multitude of safety and ethical concerns with grafting neural stem 
cells some of which are cognitive impairment, tumor development, migration to 
unintended areas, undesirable differentiation, and genetic and epigenetic changes in the 
cell population (Mathews et aL, 2008). In about 15% of Parkinson's patients, neural 
transplantation induced dyskinesia and over time cells inside the neural engraftment 
take on the pathology of Parkinson's disease (Brundin et aL, 2010, Lane et aL, 2010). 
Most concerning is the possibility of the donor cells developing into tumors as was the 
case with a boy who receive intrathecal and intracerebral injection of fetal human neural 
stem cells and later developed a donor-derived brain tumor (Amariglio et aL, 2009). For 
these reasons, many scientists have switched their focus from engraftment to stimulation 
of endogenous targets that promote neurogenesis which now appears to be a more 
practical approach in light of the growing controversies involving engraftment in humans 
or human-non-human primates engraftments (Greene et aL, 2005, Mathews et aI., 
2008). 
Ciliary Neurotrophic Factor 
Many endogenous molecules have been found to regulate adult CNS 
neurogenesis (Lie et aL, 2004, Hagg, 2005, Ming and Song, 2005, Hagg, 2009, Suh et 
aL, 2009, Bath and Lee, 2010). Endogenous ciliary neurotrophic factor (CNTF) is 
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responsible for approximately 30% of neurogenesis in the SVZ as shown in CNTF-/-
mice and by blocking CNTF antibody injections (Emsley and Hagg, 2003, Yang et aI., 
2008). We have focused our attention on CNTF because it is produced almost 
exclusively in the nervous system (Stockli et aI., 1989, Ip, 1998) and would therefore be 
a good target for indirect stimulation of neurogenesis by administration of systemic small 
molecule drugs. By indirectly stimulating CNTF in the specific environment in which we 
wish to induce a neurogenic response, we can avoid issues with low CNS bioavailability 
and undesirable side effects associated with systemically delivered CNTF such as fever, 
fatigue, and weight loss (Miller et aI., 1996, Thoenen and Sendtner, 2002). In culture, 
CNTF drives precursor cells to differentiate into astrocytes (Bonni et aI., 1997). 
However, an intraventricular injection of CNTF increased proliferation in the SVZ, but did 
not seem to affect the normal neuronal cell fate (Emsley and Hagg, 2003). Thus, CNTF 
may be a good target for indirect stimulation to make more new neurons in the adult 
CNS. 
Previously, we have shown that dopamine from the nigrostriatal projections 
induce neurogenesis via 02 receptors and that this is entirely mediated by astroglial 
CNTF (Baker et aI., 2004, Yang et aI., 2008). This is consistent with the fact that 02 
receptors inhibit cAMP (Vallar and Meldolesi, 1989, Kalkman et aI., 2003), whereas 
CNTF is under negative regulation by cAMP in astrocytes (Carroll et aI., 1993, Rudge et 
aI., 1994). Astrocytes are our target instead of neurons because the astrocytes are 
spared in neurodegenerative diseases whereas the neurons are dead, dying or 
dysfunctional therefore they would not be a good target for neuroregeneration. With 
further research, the astrocytes can be pharmacologically induced to become a factory 
for endogenous production of various factors such as CNTF. In order to decrease 
systemic side effects of the drugs used to stimulate the 02 receptor, a low dose 
combination with a similar acting drug might be more beneficial. 
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Serotonin 
The serotonin receptors, 5-hydroxytryptamin receptor or 5HT receptors are a 
group of G coupled protein receptors (excitatory and inhibitory) with the exception of 
5HT3 which is a ligand-gated Na+ and K + cation channel (Maricq et aI., 1991). 
Serotonin receptors include 7 different families 1,2, 3, 4, 5, 6, and 7 with subtypes 
signified with a, b, c, etc. (Hoyer et aI., 2002, Savitz et aI., 2009). 5HT receptors have a 
wide array of functions ranging from modulation of mood (anxiety and depression), 
cognition, learning, memory, aggression, appetite, migraines, REM sleep, pain 
processing, and release of a number of neurotransmitters and hormones. 5HT 
receptors, in the periphery, facilitate smooth muscle contraction, platelet aggregation, 
gastrointestinal function, and impact upon pain processing. The 5HT1 receptor family is 
characterized as a seven transmembrane domain receptor which upon activation, 
couples to regulatory G proteins that negatively regulates/inhibit adenylyl cyclase (AC) 
resulting in a decrease of cAMP (Mendez et aI., 1999, Azmitia, 2001, Kalkman et aI., 
2003, Vanhoose et aI., 2004). We would expect this decreased cAMP to increase CNTF 
as we have seen with the 02 receptor leading to an increase in neurogenesis (Yang et 
al.,2008). 
Of this family, we have chosen to pursue serotonin receptor 5HT1A because of 
its regulatory role in decreasing cAMP and its location in the two neurogenic niches of 
the brain. When most people talk about the 5HT1A receptor they are referring to the 
neuronal 5HT1A receptor; however, the 5HT1A receptors were also found to be 
expressed on subset of GFAP+ cells in the lateral septal nucleus and the polymorphic 
layer of the OG (Whitaker-Azmitia et aI., 1993). In addition to astrocytes with 5HT1A 
receptors, neuronal 5HT1A is found in the serotonergic projections from the raphe nuclei 
to the SVZ overlap with dopaminergic fibers in the SVZ where neurogenesis occurs and 
where a high expression of CNTF is found; likewise, in the hippocampus, neuronal 
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5HT1A is located in the soma and dendrites of large interneurons (Azmitia et aI., 1992). 
It is important to know the location and type of neuronal 5HT1A receptor since the 
autoreceptors found in the serotonergic projections from the raphe nuclei to the SVZ 
have the potential to inhibit or "put the brakes on" serotonin induced activity and their 
regulation can be affected by 5HT1A agonist; however, the 5HT1A receptors in the 
hippocampal formation are not affected by agonist treatment as they are heteroreceptors 
(Riad et aI., 2001). Interestingly, 5HT1A receptor is found in highest abundance in 
astrocytes in the two regions of the brain where neurogenesis occurs throughout life. 
The 5HT1 A receptor is found in ninety percent of the astrocytes that are located in the 
lateral septa which is adjacent to the subventricular zone; however the greatest 
abundance of the 5HT1A receptor is in the polymorphic layer or hilus of the DG 
(Whitaker-Azmitia et aI., 1993). 
Pharmacological stimulation of serotonin receptors and neurogenesis 
Depression is thought to cause a decrease in neurogenesis or vice versa, but the 
exact link between these two is still unclear (Kempermann et aI., 2008, Thomas and 
Peterson, 2008). Furthermore, neurogenesis as an indicator for effective antidepressant 
activity of serotonin is still under debate. In 129Sv/Ev mice, the antidepressant effects of 
Fluoxetine was seen to increase neurogenesis; however, within the same lab this finding 
could not be replicated with BALB/cJ mice (Santarelli et aI., 2003, Holick et aI., 2008) or 
BALB/cJ and C57BLl6J mice in another laboratory (Navailles et aI., 2008). 
Serotonin or activation of the serotonin receptor has been shown to increase 
neurogenesis in both the SVZ and SGZ in adult rats (Brezun and Daszuta, 1999, Brezun 
and Daszuta, 2000, Banasr et aI., 2004, Daszuta et aI., 2005, Huang and Herbert, 2005, 
Zhang et aI., 2009, Soumier et aI., 2010). Additionally, a landmark study (Santarelli et 
8 
aI., 2003) showed hippocampal neurogenesis in adult mice, and the effects of 
antidepressants, are regulated specifically through the 5HT1A receptor, using 5HT1A-/-
mice and 8-0H-DPAT, which is a selective agonist for the 5HT1A receptor (Middlemiss 
and Fozard, 1983). In Chapter 2, our studies into the role of serotonin 1a agonist, 8-0H-
DPAT, in regulating CNTF and adult neurogenesis in the SVZ and SGZ of mice and rats 
will be discussed. 
Spinal Cord Injury 
Spinal cord injury begins with the shear mechanical injury which causes tissue 
damage, i.e., neuronal and glial death, damage to axons, and destruction of blood 
vessels at the injury site. The initial insult is just the beginning of the pathology that 
ensues afterwards. Subsequently, a secondary injury occurs due to inflammation in 
response to the tissue damage. This inflammation has been shown to have both 
detrimental and beneficial properties (Donnelly and Popovich, 2008, Kigerl et aI., 2009). 
This inflammation can continue chronically after injury (Fleming et aI., 2006). Within two 
weeks a glial scarring begins to form around the epicenter isolating it from the healthier 
tissue (Berry et aI., 1983). 
The initial inflammatory response begins within an hour of the primary injury as 
indicated by a massive rise in TNFa mRNA (Harrington et aI., 2005) along with IL-6 and 
IL-1 ~ mRNA (Donnelly and Popovich, 2008). Furthermore, in mice, astrocytes are 
thought to be responsible for the initiation of the inflammatory response (Pineau et aI., 
2010). It is these glial cells that can release cytokines such as TNFa, a key player in the 
synaptic plasticity, inflammatory pain, and allodynia (Peng et aI., 2006, Zhang et aI., 
2011 b). Several ADAMs (a disintegrin and metalloproteinase) such as ADAM 1 0, 
ADAM17 (aka TACE), and ADAM19 are known to be involved in the ectodomain 
9 
shedding of TNFa (Hooper et aI., 2005). MMP9 (matrix metalloproteinase 9) plays a 
detrimental role and a general metalloproteinase inhibitor greatly improve outcomes 
following spinal cord injury (Noble et aI., 2002). Metalloproteinases are central 
regulators of tissue remodeling, inflammation, plasticity, and signal transduction. In the 
CNS, metalloproteinases have implications in a vast array of diseases to include 
cerebral ischemia, spinal cord injury, multiple sclerosis, epilepsy, neuropsychiatric 
disorders, and neurodegenerative disorders (Rivera et aI., 2010). Although some 
studies have been done on a select few metalloproteinases, they are highly under 
studied in the CNS, particularly, the ADAMs family. Therefore, they make a great topic 
for further investigation. 
Wildtype ADAM21 Hypothesis 
[--:> I Pain and/or Sprouting I 
ADAM21 deficient 
[+!ain and/or Sprouting I 
The Metzincin Superfamily 
The metzincin superfamily is comprised of several families, two of which are the 
Matrixins and Adamalysin families (Bode et aI., 1993, Gomis-Ruth, 2009). The 
metzincin superfamily consists of multi-domain proteins that are named for the 
conserved Methionine in the zinc dependent catalytiC site of the metalloproteinase which 
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contains an extended zinc binding motif (HEXXHXXGXXH) followed by the highly 
conserved "Met-turn" (a 1 ,4-I3-turn found directly below the zinc binding site which 
contains Methionine in the 3 position) (Bode et aI., 1993, Stocker and Bode, 1995, 
Stocker et aI., 1995, Gomis-Ruth, 2009, Tallant et aI., 2010). There are four 
endogenous inhibitors of metalloproteinases, tissue inhibitors of metalloproteinases 
(TIMP1-4), which can modulate the activity of the metalloproteinases (Brew and Nagase, 
2010). The Matrixin family is comprised of several subfamilies of matrix 
metalloproteinases (MMPs) which include collagenases, gelatinases, membrane-type 
MMP, stromelysins, matrilysons, enamelysins, metalloelastases and others (Vu and 
Werb, 2000). The Adamalysin family is comprised four subfamilies: ADAM proteins (a 
disintegrin and metalloproteinase), ADAMTS proteins (a disintegrin and 
metalloproteinase with thrombospondin motif), ADAMTSL proteins (with 
thrombospondin-like motif), and SVMP proteins (snake venom metalloproteinase) 
(Stocker et aI., 1995, Rivera et aI., 2010). 
ADAM proteins 
The ADAM proteins contain a prodomain, metalloproteinase domain, disintegrin 
domain, cysteine rich region, EGF-like repeat, transmembrane domain, and cytoplasmic 
tail (Wolfsberg et aI., 1995, Yang et aI., 2006, Edwards et aI., 2008, Klein and Bischoff, 
2011). The ADAMs are most widely known for their sheddase activity which cleaves off 
the ectodomain of a membrane bound protein and releasing it into the extracellular 
space. The ADAMS family includes a group of enzymes known as a-secretases that 
cleave amyloid precursor protein. It has been suggested that ADAM9, ADAM10, and 
ADAM17 may form a complex that is associated with decreases of amyloid 13 peptide 
(AI3), thus reducing plaque formation in the normal brain (Asai et aI., 2003, Postina et aI., 
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2004). Ectodomain shedding by ADAMs and other sheddases is used for releasing 
signaling molecules, cell adhesion molecules, receptors, and cleavage of other 
extracellular proteins (Hooper et aL, 2005) This gives ADAMs the ability to regulate 
gene transcription, signaling and cellular adhesion. ADAM17 was the first ADAM in 
which a substrate was found and has since been the main focus among ADAMs due to 
its sheddase activity on TNFa (Black et aL, 1997, Moss et aL, 1997). Following spinal 
cord injury, TNFa is increased within an hour whereas TNFR1 does not increase in the 
spinal fluid until 3 to 6 hours after initial insult (Harrington et aL, 2005). TNFa induces 
expression of ADAM8 which cleaves TNFa receptor 1 (TNFR1), TNFR1 irreversibly 
binds free TNFa resulting in feedback inhibition (Bartsch et aL, 2010). Our lab has 
shown ADAM8 expression to increase in endothelial cells and be involved in 
angiogenesis following spinal cord injury (Mahoney et aL, 2009). A substrate of 
ADAM 1 0 is fractal kine (CX3CL 1), a chemokine that induces inflammation and leukocyte 
migration (Hundhausen et aL, 2007); it can be released from neurons to contribute to the 
pain pathway as shown by intrathecal injection of fractalkine resulting in thermal and 
mechanical allodynia (Milligan et aL, 2004, Milligan et aL, 2005). This substrate is 
common between ADAM10 and ADAM17; however, ADAM10 has constitutive activity 
towards fractalkine whereas ADAM17's activity is inducible (Garton et aL, 2001). After 
spinal cord injury the metalloproteinase domain of ADAMs can playa diverse role in the 
regulation of many processes including inflammation and pain development. 
The metalloproteinase domain of ADAM proteins is confined by the pro-domain 
containing a cysteine switch rendering it inactive until cleavage of the prodomain occurs. 
ADAM8 and ADAM28 have been shown to have autocatalytic activity, removing the 
prodomain without the aid of another protein (Howard et aL, 2000, Schlomann et aL, 
2002). In humans, several ADAMs, ADAM2, ADAM11, ADAM18, ADAM22, ADAM23, 
and ADAM32, are predicted to have an inactive metalloprotease domain due to the 
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absence of a the Zn-binding motif seen in other ADAMs (Andreini et aL, 2005, Hooper et 
aL, 2005) which would suggest that in those ADAMs, the primary function of the protein 
would most likely involve cell-cell or cell-matrix interaction via integrins binding to the 
disintegrin domain. 
Next to the metalloproteinase domain, ADAMs contain a characteristic disintegrin 
domain found only in snake venom metalloproteinases (SVMP) and ADAMs. The 
disintegrin domain was first found in SVMP; the disintegrin domain binds integrins on 
platelets in order to prevent (thus, dis-integrin) fibrinogen binding resulting in 
anticoagulant properties (Gould et aL, 1990).This type of domain is unique in 
transmembrane proteins due to the combination with the metalloproteinase and the 
disintegrin loop. The disintegrin loop found in ADAMs and PIli SVMP have a distinctive 
alignment of the cysteine residues linked by disulfide bonds (Gould et aL, 1990, Calvete 
et aI., 2003, Hooper et aL, 2005). With the exception of ADAM15, none of the ADAMs 
contain a traditional RGD ligand binding site in the disintegrin domain (Kratzschmar et 
aI., 1996), but the disintegrin loop structure (canonical disintegrin loop motif; 
CRXXXXXCDXXEXC) containing alternative integrin binding sequence (mostly ECD or 
XCD ) are also capable of integrin binding (Bigler et aI., 2000, Zhu et aL, 2000, Evans, 
2001, Hooper et aL, 2005, Lu et aL, 2007). 
As mentioned above, ADAM8 is present in endothelial cells and thought to be 
involved in angiogenesis following spinal cord injury, but whether the metalloproteinase 
or the disintegrin domain is involved in the angiogenic response is not yet clear 
(Mahoney et aL, 2009). After an injury to the brain, a beta3-containing integrin found on 
astrocytes binds to Thy-1 resulting in conversion of astrocytes into reactive astrocytes 
(Avalos et aL, 2004). Additionally, ADAM8 and ADAM33 have been associated with the 
inflammatory asthma although the mechanism of action is not clear (King et aL, 2004, 
Haitchi et aI., 2005, Jie et aL, 2009, Koller et aL, 2009). If we could elucidate the 
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mechanism by which these molecules participate in the disease process, we could apply 
that knowledge to other system as well. Moreover, the unique combinations of these 
various domains make ADAMs a particularly good target for therapeutic drug 
intervention. Currently, selectivity of metalloproteinase inhibitors is a problem with the 
high degree of homology at the catalytic site (Fisher and Mobashery, 2006, Corbitt et aI., 
2007, Jacobsen et aI., 2010). However, some degree of selectivity was achieve with 
GI254023X which inhibits ADAM 17 and ADAM 10, but is preferential to the constitutive 
activity of cleavage of fractalkine by ADAM10 (Ludwig et aI., 2005) For the disintegrin, 
small peptides that mimic the disintegrin loop can be used as a competitive antagonist 
similar to the study with a small peptide resembling the ADAM8 disintegrin binding 
domain which resulted in enhanced protection of experimentally induced autoimmune 
diseases (Schluesener, 1998). Therefore, drug development against the 
metalloproteinase and/disintegrin domain holds promise for later clinical use. 
Metalloproteinases in Spinal cord injury 
Spinal cord injury has not been widely investigated in terms of ADAM protein 
involvement. Apart from expression data, the literature on ADAM proteins following a 
spinal cord injury thus far is limited to our lab's finding that ADAM8 has a potential role in 
angiogenesis with selective up-regulation localized in the endothelial cells of blood 
vessels following spinal cord injury (Mahoney et aI., 2009). In an unpublished 
subsequent study, we found no overt phenotype following a contusive spinal cord injury 
in ADAM8 deficient mice. Unlike ADAMs, a few MMPs have been found to playa 
significant role in resulting pathology after a spinal cord injury (Zhang et aI., 2011 a). For 
example, MMP9 has been found to be up regulated after spinal cord injury within 24 
hours after spinal cord injury and deletion of MMP9 lead to an increase in functional 
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recovery and reduced inflammation due to a reduced barrier disruption (de Castro et aI., 
2000, Noble et aI., 2002). Whereas, MMP2 expression was delayed compared to MMP9 
expression and did not increase until day 5 and in MMP2 deficient mice there was an 
compensatory increase in MMP9, decreased white matter sparing, impaired functional 
recovery and increased reactive astrogliosis (de Castro et aI., 2000, Hsu et aI., 2006). 
MMP9 and MMP2 give an example of how a metalloproteinase can be deleterious or 
beneficial. Due to the similarities in the metalloproteinase domains of MMPs and 
ADAMs, we can hypothesize that the metalloproteinase activity of any ADAM would 
have a potential beneficial and/or detrimental role in the pathological events following 
spinal cord injury. ADAM21 contains a catalytically active metalloproteinase (Hooft van 
Huijsduijnen, 1998) and is found to be present in highly plastic regions in the developing 
and adult brain such radial glia lineage cells in the neurogenic niche of the subventricular 
zone and in new primary olfactory neurons and their growing axons (Yang et aI., 2005). 
After spinal cord injury there is a shift in the balance of excitatory and inhibitory 
innervation due to the damage or death to the neurons. In addition, as the inflammatory 
processes begin astrocytes increase and can become reactive releasing excess 
modulatory factors. This can exacerbate the balance of excitatory and inhibitory signals 
leading to sprouting of pain fiber into the area of the spinal cord responsible for 
responses to non-noxious stimuli (Kuner, 2010). Since ADAM21 is present where 
noxious pain fibers reside in the dorsal horn of the spinal cord, they are likely to be 
involved in the inflammation or plasticity that results after insult to the spinal cord. The 
localization of ADAM21 in the adult CNS leads to the possibility that ADAM21 has a role 
in coordinating the repair/migration processes that follow spinal cord injury. Therefore, 
inhibition of ADAM21 could be important to preventing chronic pain or inflammation after 
spinal cord injury. 
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In the study in Chapter 3, we have used ADAM21-deficient mice to examine the 
role of ADAM21 following a contusive spinal cord injury in locomotion, balance, thermal 
nociception, as well as histological outcomes: spared white matter, CGRP and GFAP at 
the epicenter and the penumbra. In Chapter 4, we investigated the possible 
compensation of other metalloproteinases and the regulatory role of ADAM21 following 
spinal cord injury in ADAM21-deficient mice. Chapter 5 discusses the implications of the 
findings from Chapter 2, 3, and 4 and their potential implications to humans. 
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CHAPTER TWO 
SEROTONIN 1A RECEPTOR INCREASES SPECIES- AND REGION-SELECTIVE 
ADULT CNS NEUROGENESIS, BUT NOT THROUGH CNTF 
INTRODUCTION 
Neurogenesis in the adult mammalian brain occurs predominantly in the SVZ of 
the lateral ventricles and the SGZ of the hippocampal dentate gyrus (Ming and Song, 
2005, Hagg, 2009, Kriegstein and Alvarez-Buylla, 2009, Suh et aI., 2009, Soumier et aI., 
2010). SVZ neuroblasts migrate along the rostral migratory stream to the olfactory bulb 
and SGZ neuroblasts migrate into the neighboring granule cell layer where they become 
integrated neurons or die (Luskin, 1993, Lois and Alvarez-Buylla, 1994, Winner et aI., 
2002). 
Many endogenous molecules regulate adult CNS neurogenesis (Lie et aI., 2004, 
Hagg, 2005, Ming and Song, 2005, Hagg, 2009, Suh et aI., 2009, Bath and Lee, 2010). 
CNTF is responsible for -30% of SVZ neurogenesis as shown in CNTF-/- mice and by 
antibody injections (Emsley and Hagg, 2003, Yang et aI., 2008). We study CNTF 
because it is produced almost exclusively in the nervous system (Stockli et aI., 1989, Ip, 
1998) and would therefore be a good target for indirect stimulation of neurogenesis by 
systemic small molecule drugs. We found that nigrostriatal projections induce 
neurogenesis via D2 dopamine receptors which is entirely mediated by astroglial CNTF 
(Baker et aI., 2004, Yang et aI., 2008). This is consistent with the fact that D2 receptors 
inhibit cAMP in astrocytes (Vallar and Meldolesi, 1989, Kalkman et aI., 2003), whereas 
CNTF expression is inhibited by cAMP in astrocytes (Carroll et aI., 1993, Rudge et aI., 
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1994). CNTF is predominately produced by astrocytes (Sendtner et aI., 1994, Oallner et 
aI., 2002) which are spared in most neurodegenerative diseases. Therefore, they are 
ideal pharmacological targets to serve as CNTF "factories" to enhance endogenous 
neurogenesis. This would also circumvent the peripheral side effects and low 
bioavailability seen with systemic administration of CNTF (Thoenen and Sendtner, 
2002). 
We wanted to find additional cAMP-inhibiting drugs to increase CNTF, as they 
could be combined with low doses of 02 agonists to reduce systemic drug doses and, 
consequently, side effects. 5HT1A is expressed on a subset of astroglia throughout the 
brain, in addition to neurons in the raphe nuclei (Whitaker-Azmitia et aI., 1993). Their 
activation decreases cAMP levels (Mendez et aI., 1999, Azmitia, 2001, Kalkman et aI., 
2003, Vanhoose et aI., 2004). Colocalization of 5HT1A and GFAP is among the highest 
in the polymorphic layer of the dentate gyrus (Whitaker-Azmitia et aI., 1993). 
Interestingly, serotonergic and dopaminergic projections to the SVZ overlap where 
neurogenesis and high expression of CNTF are located (Hagg, 2005). Activation of 
5HT1A increases neurogenesis in the SVZ and SGZ in rats (Brezun and Oaszuta, 1999, 
Banasr et aI., 2004, Huang and Herbert, 2005, Soumier et aI., 2010). A landmark study 
(Santarelli et aI., 2003) showed that hippocampal neurogenesis in 129SvEv mice and 
the effects of antidepressants are regulated through 5HT1A, using 5HT1A-/- mice and 8-
OH-OPAT. Acute but not chronic 8-0H-OPAT treatment increases SGZ proliferation in 
C57BLl6J mice (Klempin et aI., 2010). Here, we tested whether CNTF mediates the 
neurogenic effects of 8-0H-OPAT in the SVZ and SGZ of adult C57BLl6J and 129SvEv 
mice, as compared to rats. 
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MATERIAL AND METHODS 
Animals 
A total of 116 mice were used, Le., 64 CS7BLl6J adult male mice (8-12 wks, 20-
30g, stock # 000664, Jackson Laboratory, Bar Harbor, ME, USA), 40 129SvEv adult 
male mice (model # 129SVE-M [129S6/SvEvTac], 11 wks, 20-30 g, Taconic, Hudson, 
NY, USA), and 12 wild type background of our CNTF mice (essentially CS7BLl6) were 
used. In addition, 10 adult male Sprague-Dawley rats (280-3S0g, Harlan, Indianapolis, 
IN) were used. The average weight of the animals in each experimental group was the 
same. All invasive procedures in mice were performed under deep anesthesia obtained 
by an intraperitoneal injection of 0.4 mg/g body weight Avertin (2,2,2-tribromoethanol in 
0.02 ml of 1.2S% 2-methyl-2-butanol in saline, Sigma-Aldrich, St Louis, MO, USA). Rats 
were anesthetized with an intramuscular injection of a mixture (62.S !Jg/g weight of the 
animal) containing S ml of ketamine (SOO mg/ml, Hospira, Lake Forest, IL), O.S ml of 
acepromazine (10 mg/ml, ButlerSchein, Dublin, OH), and 1.2 ml xylazine (20 mg/ml, 
Akorn, Decantur, IL) diluted in 13.3 ml of 0.9% saline. All animal procedures were 
performed according to University of Louisville Institutional Animal Care and Use 
Committee protocols and the National Institutes of Health guidelines. 
5HT1A agonist treatment and BrdU injection protocols 
The animals were given saline or (R)-(+)-8-Hydroxy-DPAT dissolved in saline (1 
mg/kg/day, Cat # H-140; Sigma-Aldrich, St. Louis, MO), a full and specific SHT1A 
agonist and active enantiomer of (±)-8-hydroxy-DPAT. It was administered either Lp. 
once daily for 3 days or s.c. via Alzet pump (Cat # 10030 with a flow rate of 1 !JI/day for 
3 days, or Cat # 1002 with a flow rate of 0.2S !JI/day for 14 days or Cat #: 1004 with a 
flow rate of 0.11 !JI/day for 28 days; Durect Corp., Cupertino, CA). The 14 day pumps 
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were replace on day 14 with a new 14-day pump with fresh reagent for the 28-day 
infusion in C57BLl6J mice. 5-Bromo-2'-deoxyuridine (BrdU; Cat #: B5002, Sigma-
Aldrich, St. Louis, MO) was injected at 50 mglkg twice daily for 3 days with the final 
injection 2 hrs before processing for histology. 
mRNA measurements by quantitative real-time reverse transcription-PCR (qPCR) 
To obtain total RNA, each sample was isolated from freshly dissected 0.5 mm 
wide SVZ strips or the entire hippocampal formation, flash frozen using liquid nitrogen, 
and isolated from a commercial kit (Cat #: 74104, Qiagen, Valencia, CA). Briefly, 1 I..Ig 
RNA was ONAsed (Cat #: 18068-015, Invitrogen, Carlsbad, CA) and used as templates 
for reverse transcription, which included 1 1..11 of a 0.5 1..1 gl 1..1 I random primers (Cat# : 
C1181,Promega, Madison, WI), 1 I..Ig total RNA, 51..11 of 5x buffer, 1.251..11 of 10 mM dNTP 
mix, 2.25 1..11 RNAse free water, and 1 1..11 (200 units) of Moloney Murine Leukemia Virus 
Reverse Transcription (M-MLV RT, Cat #: M170, Promega, Madison, WI) and heated at 
3rC for 1 hr. Water was used as a no-template control instead of total RNA. The 
qPCR was performed using primer sets specific for CNTF (Mm00446373_m1 and 
Rn00755092_m1), Nos1 (Mm00435175_m1 and Rn00583793_m1), HTR1A (5HT1A; 
Mm00434106_s1 and Rn00561409_s1), GapOH (4352339E), and Ywhaz (Rn00755072) 
(all from Applied Biosystems, Carlsbad, CA). 
Histology 
Mice were transcardially perfused with ice-cold PBS, pH 7.4, until the liver 
became clear (approx. 10-20 ml) followed by 10 ml of ice-cold 4% paraformaldehyde in 
0.1 M phosphate buffer. Brains were dissected out and immediately placed in ice-cold 
4% paraformaldehyde to postfix overnight followed by cryoprotection in 30% sucrose in 
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0.1 M phosphate buffer overnight. Serial coronal brain sections of 30 IJm thick were cut 
on a Leica SM 2000R freezing stage sliding microtome and stored in anatomical order in 
24-well plates filled with Millonig's buffer. Double immunofluorescent staining for GFAP 
(MAB3402, 1: 1 000, Millipore, Billerica, MA) and 5HT1 A (AB5406, 1 :300, Millipore, 
Billerica, MA) was performed using appropriate secondary antibodies conjugated with 
Alexa488 (1 :500 goat anti-mouse) and Alexa546 (1 :500; goat anti-guinea pig; Molecular 
Probes; Eugene, OR). For BrdU staining, starting at a random point along the 
rostrocaudal axis of the brain sections stained included those approximately between 
stereotaxic coordinates (caudal to Bregma) 1.18 to 0.14 mm for SVZ and -1.34 to -3.08 
mm for hippocampal formation in the mouse (Franklin and Paxinos, 1996). Sections for 
rats were approximately between 1.6 to 0.2 mm for SVZ and -2.3 to -4.52 mm for 
hippocampal formation in the rat (Paxinos and Watson, 1986). Every sixth section (180 
IJm apart) through the SVZ and hippocampal formation was immunostained against 
BrdU (MAB3510, mouse IgG, clone BU-1, 1 :100,000; Millipore, Billerica, MA). Briefly, 
brain sections were incubated in 50% formamide in 2X SSC at 65°C for 2 h, rinsed in 
fresh 2X SSC, incubated in 2N HCI at 3rC for 30 min, neutralized in 0.1 M boric acid, 
pH 8.5, for 10 min. Next, sections were sequentially incubated in 10% normal horse 
serum for 30 min, primary antibody overnight at 4°C, biotinylated horse anti-mouse IgG 
(1 :800; Vector Laboratories, Burlingame, CA) for 1 hr, and avidin-biotin complex 
conjugated with peroxidase for 1 hr (1 :600; Vector Laboratories). All incubations were 
carried out at room temperature unless otherwise noted. In between steps, the sections 
were rinsed 3 x 10min. The chromogen reaction was performed with 0.04% 3,3'-
diaminobenzidine (05637, Sigma-Aldrich) solution containing 0.06% nickel ammonium 
sulfate and 1 % hydrogen peroxide in 0.05 M Tris buffer-HCI. Sections were then rinsed 
in 0.1 M phosphate buffer, mounted on gelatin coated glass slides in anatomical order, 
and cover slipped in Permount (SP15, Thermo Fisher Scientific, Pittsburg, PA). 
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Unbiased stereological counts and statistics 
The number of BrdU+ nuclei in the SVZ of each brain was estimated using a 
motorized Leica DMIRE2 microscope and an unbiased optical fractionator stereological 
method (Stereologer; Stereology Resource Center, Chester, MD) (Baker et aI., 2004). 
For the SVZ, the reference space was defined as an -50 IJm-wide strip of the entire 
lateral of all the lateral ventricle encompassing dorsoventrally the ventral tip and the 
dorsolateral triangular regions of the lateral ventricle, rostrocaudally from the genu of the 
corpus callosum to the caudal end of the decussation of the anterior commissure, and 
laterally the boundary between the SVZ and striatum. Within the reference space, BrdU-
positive nuclei were counted in defined frames (frame size: 2000 IJm2, frame height: 15 
IJm, guard height: 2 IJm, frame spacing: 100 IJm) and the total number of BrdU-positive 
cells in a brain was calculated by the software as: n = number of nuclei counted x 
1/section sampling fraction x 1/area sampling fraction x 1/thickness sampling fraction. A 
modified unbiased stereology protocol was used to count the BrdU+ cells in the SGZ of 
the dentate gyrus (West et aI., 1991). Briefly, the total number of BrdU+ cells between 
the granule cell layer and hilus of the dentate gyrus that were within two cells body 
distance from the granular layer of the dentate gyrus was counted bilateral from the 
stereological coordinates previous stated. The total number of cells is calculated by the 
modified formula for rare events: n = number of nuclei counted x 1/section sampling 
fraction = total number of cells counted x (1/ (1/6)). All analysis was done bilaterally 
except for in rats, in which a unilateral count was performed due to the other half of the 
brain was used for mRNA analysis. All analyses were performed blindly. Statistical 
analyses were performed with the Student's unpaired t-test using Excel software 
(Microsoft, Redmond, WA). A value of p < 0.05 was considered statistically significant. 
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RESULTS 
5HT1A receptors co-localization in SVZ astrocytes in C57BU6J mice 
Astrocytes in different areas of the brain are heterogeneous populations that can 
express different amounts and types of receptors (Emsley and Macklis, 2006). 
Interestingly, 5HT1A is found in highest abundance in astrocytes of rats in the two 
regions of the brain where neurogenesis occurs throughout life (Whitaker-Azmitia et aI., 
1993). In mice, 5HT1A staining also co-localized with GFAP in the SVZ (Figure 1A-C). 
This was confirmed in confocal microscopy z-stack images showing that most of 5HT1A 
staining is co-localized with GFAP in addition to a few putative axon terminals, 
presumably presynaptic receptors of serotonergic projections (arrows in Figure 10-F). 
However, colocalization with synaptophysin remains to be done. In the dentate gyrus, 
5HT1A immunostaining is co-labeled with GFAP, including the SGZ (Figure 1G-I). 
5HT1A agonist 8-0H-DPAT does not increase neurogenesis in adult C57BU6J 
mice 
We intended to test the role of 5HT1 A directly in CNTF-/- mice and their 
littermates but wanted to first test 8-0H-OPAT in less expensive C57BLl6J mice. The 
latter are the most commonly used strain in neuropharmacological research and our 
normal strain that we currently and previously have used to show changes in SVZ 
proliferation after 3 day drug treatments (Emsley and Hagg, 2003, Yang et aI., 2008). 
Male C57BLl6J adult mice received 1 mg/kg/daily over 3 days using subcutaneous Alzet 
osmotic mini-pump containing saline or saline plus the active enantiomer of 8-0H-OPAT. 
This dose was used by others who have shown 8-0H-OPAT to promote neurogenesis in 
both rats and mice (Santarelli et aI., 2003, Soumier et aI., 2010). BrdU was injected 
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twice daily at 50 mg/kg Lp. per injection. After an unbiased stereological analysis, we 
found no differences in either BrdU+ cells in the SVZ (Figure 2A) or SGZ (Figure 2B). 
Separately, we used higher doses and found that 3 or 10 mg/kg per day bolus injections 
in the wild type background of our CNTF mice (essentially C57BLl6) also did not induce 
neurogenesis (data not shown; n=4 per group). The osmotic pump was chosen in order 
to give a constant level of drug over the 3-day drug treatment in light of the 26 min half-
life of 8-0H-OPAT in the brain (Perry and Fuller, 1989). Others have shown that the 
SGZ neurogenesis was increased following 28-day osmotic pump administration of 1 
mg/kg/day by osmotic pump (Santarelli et aI., 2003). Therefore, C57BLl6J mice 
received saline or 8-0H-OPAT for 28-days using two 14-day Alzet osmotic pumps. To 
identify proliferating cells, BrdU was injected twice-daily 50mg/kg Lp. over the last 3 days 
with the last injection two hours before sacrifice. The 8-0H-OPAT mice did not show an 
increase in BrdU+ nuclei in the SVZ (Figure 2C) or SGZ (Figure 20). Lastly, we did not 
observe the typical serotonergic behavior (forepaw treading, flat body posture, and 
weaving of the head) that has been described in rats (Tricklebank et aI., 1985) in any of 
these 8-0H-OPAT-treated mice. 
8-0H-OPAT does not increase CNTF expression in C57BU6J mice 
It was possible that 8-0H-OPAT failed to induce neurogenesis because it does 
not induce CNTF. We had shown that increases in CNTF cause increased 
neurogenesis (Emsley and Hagg, 2003, Yang et aI., 2008). There were not changes in 
CNTF mRNA in the SVZ and hippocampal formation either acutely after 3-day infusion 
(Figure 3A) or chronically after 28-day infusion (Figure 3B) in C57BLl6J mice. In the 
same tissue, we measured 5HT1A mRNA to confirm there was not a down-regulation of 
the receptor after the administration of 8-0H-OPAT. After 3 days infusion, 5HT1A was 
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decreased by -20% in the SVZ (Figure 3C), but not the hippocampal formation (Figure 
3D). Lastly, to find additional evidence for the expected effects of 8-0H-DPAT, we 
measured neuronal Nitric Oxide Synthase (nNOS) mRNA levels in the same tissue, as 
these were shown by others to decrease in the hippocampus of B6129SF2 mice 1 day 
after treatment and to diminish completely by 7 days (Zhang et aI., 2010). In our 
C57BLl6J mice, nNOS mRNA did not decrease after acute (Figure 3E) or chronic 
(Figure 3F) administration of 8-0H-DPAT. 
8-0H-OPAT does not stimulate neurogenesis or CNTF in adult 129SvEv mice 
It is possible that our negative results after 8-0H-DPAT treatment were related to 
the C57BLl6J strain. We, therefore, repeated the 8-0H-DPAT experiment of the study 
by Santarelli et al. (2003), in which they used male 129SvEv mice to show that 8-0H-
DPAT increased neurogenesis specifically through 5HT1A. Here, male 129SvEv mice 
from the same vender were first treated with a 3-day Lp. injection of saline of 1 mg/kg 8-
OH-DPAT. There was no significant change in the BrdU+ nuclei for the SVZ (Figure 4A) 
or SGZ (Figure 4B). Given the fact that the Santarelli et al. (2003) infused for 28 days 
using Alzet pumps, we next also infused saline or the same dose, 1 mg/kg/day, of 8-0H-
DPAT. There was no significant change seen in BrdU+ nuclei in either the SVZ (Figure 
4C) or SGZ (Figure 4 D). Since we did not see changes in neurogenesis, we measured 
CNTF mRNA levels and found no effects in either the SVZ or the hippocampal formation 
of acute (Figure SA) or chronic (Figure 5B) 8-0H-DPAT treatment groups. 5HT1A 
mRNA levels were not affected after acute (Figure 5C) or the chronic (Figure 5 D) 
treatments in the SVZ or SGZ. As in the C57BLl6J mice, the nNOS mRNA levels for 
both acute (Figure 5E) and chronic (Figure SF) groups were not significantly affected by 
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the 8-0H-DPAT treatment. As in the C57BLlSJ mice, we did not observe the typical 
serotonergic behavior in any of the 8-0H-DPAT-treated 129SvEv mice. 
8-0H-DPAT increases neurogenesis in adult rats, but only in the SGZ and not 
through CNTF 
Despite bioactivity in mice as shown by the decrease in 5HT1A after acute 
treatment with 8-0H-DPAT in C57BLlSJ mice, we wanted to further verify that 8-0H-
DPAT was active. The literature on the use of 8-0H-DPAT in rats is much more 
extensive, including behavioral effects (Tricklebank et aI., 1985) and its ability to 
increase hippocampal neurogenesis (Banasr et aI., 2004, Huang and Herbert, 2005, 
Soumier et aI., 2010). Thus, male Sprague-Dawley rats were injected daily i.p. with 
saline or 1 mg/kg 8-0H-DPAT over 3 days. Within minutes of 8-0H-DPAT injection the 
rats exhibited typical serotonergic behavior, verifying that our drug was effective at 
eliciting a serotonergic response. The number of BrdU+ nuclei in the SGZ was 
increased by 43% after the 3-day treatment (Figure SB, D, and F). In contrast, the SVZ 
showed no change in the number of BrdU+ nuclei (Figure SA, C, and E). Since we 
found that 8-0H-DPAT increased neurogenesis in the rat SGZ, we assessed whether 
this was mediated by an increase in CNTF. However, there were no changes in CNTF 
mRNA levels in the SVZ or hippocampal formation (Figure 7A). To test whether the 
difference between the SGZ and SVZ neurogenesis was related to the presence of 
functional 5HT1A, we measured the effects of 8-0H-DPAT on nNOS mRNA levels. The 
nNOS mRNA levels were decreased by 50% in the hippocampal formation, but were not 
affected in the SVZ (Figure 7B). Lastly, 5HT1A mRNA levels were checked to see if 
there was a down regulation of the receptor. 5HT1A was not significantly changed in the 
SVZ or SGZ (Figure 7C). 
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DISCUSSION 
Like others, we find that 8-0H-DPAT increases neurogenesis in the adult rat 
SGZ (Banasr et aI., 2004, Huang and Herbert, 2005, Soumier et aI., 2010). We wanted 
to define the role of CNTF in this neurogenic response, given the commonality between 
5HT1A and D2 receptors, i.e., both lowering cAMP and found on astrocytes. CNTF 
seems not involved in the neurogenic response to 8-0H-DPAT, as it did not increase in 
the hippocampal formation. The lack of changes in CNTF expression in rats and mice, 
and in the SVZ and hippocampal formation suggests that, unlike the D2 receptor (Yang 
et aI., 2008), 5HT1A does not inhibit cAMP in astrocytes in vivo. In fact, a recent study 
showed that the R-isoform of 8-0H-DPAT did not decrease forskolin-stimulated 
increases in cAMP in the membranes isolated from rat dorsal raphe nucleus (Valdizan et 
aI., 2010). If not CNTF, what then might regulate the neurogenic response to 5HT1A 
agonist in the rat SGZ? The difference between the neurogenic response in the SVZ 
and SGZ and its correlation with the decrease in nNOS mRNA levels suggests that 
5HT1A activation in the SGZ decreases nNOS signaling, which results in an increase in 
neurogenesis. In fact, NO appears to reduce proliferation and nNOS inhibition in the 
CNS of adult mammals causes an increase in neurogenesis in the SVZ (Matarredona et 
aI., 2005) and hippocampal formation (Nakagawa et aI., 2002a, Nakagawa et aI., 2002b, 
Gass and Riva, 2007, Gur et aI., 2007). In cultured hippocampal neurons, 8-0H-DPAT 
was shown to decrease nNOS, which decreases NO production, increasing 
phosphorylation of cAMP response element binding protein (CREB) which presumably 
increases transcription (Zhang et aI., 2010). Furthermore, in CREBal. mutant mice there 
was a 52% increase in BrdU+ nuclei in the SGZ compared to wild-type mice (Gur et aI., 
2007). Moreover, a decrease in neurogenesis was observed when CREB activity was 
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down regulated by expressing a dominant-negative CREB (Nakagawa et aL, 2002a, 
Nakagawa et aL, 2002b). Pharmacological inhibition of NO by L-NAME was shown to 
increase neurogenesis in the SVZ of adult mice (Romero-Grimaldi et aL, 2008). This 
suggests that since there were no changes observed in the mRNA levels of nNOS after 
8-0H-DPAT treatment in the SVZ of rats and the SVZ and SGZ of mice that 5HT1A 
does not modulate their nNOS levels. Besides its classical inhibition of adenylyl cyclase 
(Cornfield et aL, 1991), 5HT1A also can couple to other signaling pathways such as 
phospholipase C (Fargin et aL, 1989), mitogen-activated protein kinases (Della Rocca et 
aL, 1999) and AKT (Cowen et aL, 2005), which playa role in adult neurogenesis (Ma et 
aL, 2009, Kinsler et aL, 2010, Manning et aL, 2010). These pathways could signal 
independent of adenylyl cyclase or converge on different adenylyl cyclase subtypes to 
increase or decrease cAMP (Raymond et aL, 1999). Although the exact intracellular 
mechanism of action of 8-0H-DPAT on neurogenesis in the rat SGZ remains to be 
determined, the finding that it does not act through CNTF should enable the 
development of drug combinations. For example, one could expect an additive effect on 
the levels of SGZ neurogenesis by combining 5HT1A agonist and D2 agonists, the latter 
stimulating neurogenesis by increasing CNTF (Yanget aL, 2008). 
In rats, 8-0H-DPAT was shown to increase BrdU+ nuclei in the SVZ 4 hours after 
i.p. injection although the data for longer times were not reported (Banasr et aL, 2004). 
Our 3-day treatments did not result in any changes in SVZ BrdU+ nuclei. Other than 
strain differences, we do not know the reason for this apparent discrepancy. Thus, the 
reason for the lack of a neurogenic effect of 8-0H-DPA T in the rat SVZ remains to be 
determined, but the presence of 5HT1A in the SVZ suggests that they are not functional 
in the SVZ astrocytes under normal conditions. Others have shown that astrocytes from 
2-day old Sprague-Dawley rat pups cultured from various other brain regions express 
non-functional 5HT1A in culture (Hirst et aL, 1998). If so, this would suggest that 
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astrocytes in different eNS regions can function entirely different, as also suggested by 
their different phenotypes (Emsley and Macklis, 2006). Another possibility is that 5HT1A 
in the two different regions of the brain have differences in intracellular coupling and/or 
signaling as it has been shown with different cell types in vitro (Raymond et aI., 1999). 
The activity of 5HT1A was shown to be impacted by alterations in any of the guanine 
nucleotide-binding protein G(i), alpha subunit (Gia), in particular, alterations in the levels 
of Gia1 was shown to have a greater impact on 5HT1A activity (Liu et aI., 1999, Lin et aI., 
2002, Valdizan et aI., 2010). It remains to be determined whether there are different 
levels of the G;/Go protein isoforms accessible to the 5HT1A for coupling in the SVZ 
versus the SGZ, but it would explain why there is an apparent difference in functional 
activity. Another possibility is that 8-0H-DPAT acts on other, differently expressed, 
receptors in the two structures. The R-enantiomer of 8-0H-DPAT is considered to be 
the prototypical selective agonist for 5HT1A as shown by radio ligand binding 
(Middlemiss and Fozard, 1983). However, the use of transgenic mice and 
pharmaceutical inhibitors have shown that 8-0H-DPAT has agonistic activity on 5HT7 
(Hedlund et aI., 2004) and o2-adrenoceptors (Heusler et aI., 2010). Finally, the 
difference in the neurogenic response between the SVZ and SGZ most likely represents 
the different physiological roles of the two systems, and differences in the serotonergic 
neurons that innervate these regions. In turn, it means that hippocampal neurogenesis 
can be stimulated by 5HT1A agonists without affecting the olfactory neurogenesis, 
perhaps opening up opportunities for region-selective drug treatments to increase new 
neuron formation. 
Our results also point to remarkable differences between rats and mice with 
regards to the 5HT1A function and its role in neurogenesis. The lack of any effects of 8-
OH-DPAT in our mice, other than a 20% down-regulation of 5HT1A, suggests that the 
receptors are not fully functional in these strains of mice. Previously, 8-0H-DPAT 
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administration was shown to induce hypothermia in mice and rats to a different extent, 
suggesting the 5HT1A heterogeneity is present between mice and rats (Moser, 1991). 
In their landmark paper, Santarelli et aL (2003) report that the same dose and duration of 
8-0H-OPAT causes an increase in BrdU+ nuclei in the SGZ of 129SvEv mice but not in 
5HT1A-/- mice. The neurogenic effect of 8-0H-OPAT was replicated in 129SvEv mice 
within the same laboratory (B. Samuels, personal communication). A few differences 
might explain the apparent discrepancy between our studies. First, we used the active 
enantiomer whereas they used the racemic mixture of 8-0H-OPAT. It is unlikely that the 
S-enantiomer, a partial agonist, would have stimulated neurogenesis through other 
receptors or mechanisms, as it was ineffective in 5HT1A-/- mice (Santarelli et aI., 2003). 
Another potential difference is the stress caused by their behavioral testing resulted in a 
depressed baseline of neurogenesis in controls. Stress can have both deleterious and 
stimulatory properties depending on the type (Sa hay and Hen, 2007, Schoenfeld and 
Gould, 2011). The 129SvEv mice might be unique as the neurogenic effect of fluoxetine 
(Santarelli et aL, 2003) is not seen in BALB/cJ mice within the same laboratory (Holick et 
aL, 2008) or BALB/cJ and C57BLl6J mice in another laboratory (Navailles et aL, 2008). 
Our results are consistent with the finding that a 7 day treatment of 8-0H-OPAT did not 
increase neurogenesis whereas a single injection increased proliferation by 55% at 24 hr 
in the SGZ of C57BLl6 mice (Klempin et aL, 2010). Our 3-day data suggest that more 
than a single injection might be ineffective as a neurogenic treatment. Whatever the 
differences, we propose that 5HT1A does not playa role in normal neurogenesis in adult 
mice, although it has a clear role in rats. In fact, 5HT1A-/- mice show no differences in 
the number of BrdU+ nuclei under baseline conditions (Santarelli et aL, 2003). 
In light of the differences between rats and mice, what are the potential 
implications for the role of 5HT1A in neurogenesis in humans? This has important 
implications for the depression field because of the unresolved debate about whether or 
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not changes in neurogenesis playa role in depression (Kempermann, 2008, Thomas 
and Peterson, 2008). 5HT1A protein has an 89% homology between rats and humans, 
94% between rats and mice, and 86% between mice and humans (Clustal W Software, 
European Bioinformatics Institute, Cambridge, UK). However, there could be differences 
in the ligand binding regions or availability of coupling intracellular proteins. Also, rats 
and humans have a different neuroanatomical distribution in 3H-8-0H-DPAT binding 
(Duncan et aI., 1998). Rats have high binding in the dentate gyrus molecular layer 
whereas humans have relatively low binding. Humans and rats have high binding in CA-
1 stratum radiatum, but only humans have high binding in the CA-1 pyramidal cell layer. 
These differences could playa role in augmenting or diminishing the neurogenic effects 
seen in rats and make translation to humans more uncertain. We propose that based on 
the major species differences much more research is needed to define the potential role 
of 5HT1A in human hippocampal neurogenesis and the consequences of such a 
speculative mechanism for clinical depression. 
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Figure 1. 5HT1A is present in astrocytes in the SVZ and SGZ of adult C571B6J mice. 
5HT1A (A) and GFAP (B) are co-localized (C) in the SVz. 
Confocal microscopy shows that 5HT1A (0) and GFAP (E) are almost exclusively co-
localized (F), as indicated in the z-stack, except for a few putative axon terminals, 
presumably presynaptic receptors of serotonergic projections (arrows). In the dentate 
gyrus, 5HT1A (G) and GFAP (H) also shows co-localization (I), including in the SGZ. 
Scale bar 100 IJm (A-C, H-I), 10 IJM (O-F). CC = corpus callosum, GCl = granule cell 
layer, H = hilus, lV = lateral ventricle , STR = striatum. 
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Figure 2. 5HT1A agonist 8-OH-OPAT does not increase proliferation in C57816J mice. 
R-8-0H-DPAT was administered s.c. with a dose of 1 mg/kg delivered via Alzet osmotic 
pump for either 3 days or by two 14-day Alzet pumps for a total of 28 days to C57B/6J 
male mice. There were no significant changes in BrdU+ nuclei acutely after 3 days, in 
the SVZ (A) or SGZ (B) or chronically after 28 days in the SVZ (C) or SGZ (D). BrdU 
was given i.p. twice daily for 3 consecutive days with the last injection 2 hours before 
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Figure 3. 8-0H-OPAT does not alter CNTF or nNOS mRNA, but reduces 5HT1A mRNA 
levels in C57BI6J mice. 
CNTF mRNA levels were not changed acutely (A), after 3 days, or chronically (8), after 
28 days of 5HT1A agonist treatment in the SVZ and hippocampal formation. 8-0H-
OPAT did cause a significant decrease in 5HT1A mRNA levels (C) (p=O.0499) in the 
SVZ but not the hippocampal formation after 3 days of 1 mg/kg of 8-0H-OPAT. 5HT1A 
mRNA levels did not change in the SVZ or HF after 28 days of 8-0H-OPAT infusion (0). 
nNOS mRNA levels in the SVZ and hippocampal formation did not significantly change 
acutely (E) or chronically (F). * signifies p<O.05, n= 4, 5, 6 in each group for saline 3 
day, 8-0H-OPAT 3 day, and 28 day, respectively. 
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Figure 4. 8-0HDPA T does not increase proliferation in the SVZ or SGZ in 129SvEv 
mice. 
R-8-0H-DPAT was administered with a dose of 1 mg/kg delivered either by daily i.p. 
injection for 3 days or s.c. via Alzet osmotic pump for 28 day to 129SvEv male mice. 
There were no changes in the number of BrdU+ nuclei in the SVZ (A) or SGZ (B) acutely 
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Figure 5. 8-0H-OPAT does not alter mRNA levels of CNTF, 5HT1A or nNOS in 
129SvEv mice. 
CNTF mRNA levels were not changed acutely (A), after 3 days, or chronically (8), after 
28 days of treatment in the SVZ and hippocampal formation . 8-0H-OPAT did not cause 
a significant decrease in 5HT1 A mRNA levels in the SVZ or hippocampal formation after 
3 days (C) or 28 days (0) of 1 mg/kg of R-8-0H-OPAT. nNOS mRNA levels in the SVZ 
and hippocampal formation did not significantly change acutely (E) or chronically (F). n= 
5 in each group. 
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Figure 7. 8-0H-OPA T induces rat SGZ 
neurogenesis, decreases nNOS mRNA 
levels, but does not increase CNTF mRNA 
levels. 
A) There was no difference in CNTF mRNA 
levels in the SVZ or in the hippocampal 
formation , where neurogenesis was observed 
in the SGZ after 8-0H-DPAT treatment. B) 
There was a sign ificant decrease in nNOS 
mRNA levels only in the hippocampal 
formation and not in the SVZ. C) There were 
no changes in 5HT1 A mRNA levels in the SVZ 
or hippocampal formation. * signifies p<O.01 , 
n= 5 in each group. 
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CHAPTER THREE 
ADAM21-DEFICIENT MICE HAVE NO APPARENT PHENOTYPE 
BEFORE OR AFTER SPINAL CORD INJURY 
INTRODUCTION 
The ADAMs are multi-domain transmembrane proteins, constituting a subfamily 
of the metzincin superfamily, and mostly known for their proteolytic sheddase activity 
and their integrin-binding properties (Wolfsberg et aL, 1995, Yang et aL, 2006). MMPs 
are similar in the N-terminus to ADAMs as they contain a prodomain and 
metalloproteinase domain, but ADAMs also are comprised of several additional 
domains: disintegrin, cysteine rich, EGF-like repeat, and cytoplasmic tail (Edwards et aL, 
2008). The ADAMs have been linked to several disease processes such as asthma 
(King et aL, 2004, Haitchi et aL, 2005), inflammation (Charrier-Hisamuddin et aL, 2008, 
Koller et aL, 2009, Pruessmeyer and Ludwig, 2009), wound healing (Charrier et aL, 
2005, Hodgkinson et aI., 2010), cancer (Lu et aI., 2008), and neurological diseases 
(Gerst et aL, 2000, Barrette et aI., 2010). The metalloproteinase is of interest because of 
the potential for drug intervention with a small molecule that could inhibit its catalytic 
activity. 
MMPs have been widely studied in the brain (Agrawal et aL, 2008) and found to 
be differentially regulated after spinal cord injury (Zhang et aI., 2011 a). Deletion of the 
metalloproteinase genes MMP9 (Noble et aL, 2002) and MMP12 (Wells et aL, 2003) 
resulted in improved functional recovery and reduced/attenuated barrier disruption 
following spinal cord injury. Conversely, deletion of MMP2 resulted in impairment of 
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locomotor recovery, reduced white matter sparing, and widespread reactive astrogliosis 
following spinal cord injury (Hsu et aI., 2006). 
However, the literature on ADAMs after spinal cord injury, with the exception of 
expression data, is limited to our finding that ADAM8 is association with angiogenesis 
after spinal cord injury (Mahoney et aI., 2009). ADAM8-/- mice do not have an overt 
phenotype following spinal cord injury (Arnold and Hagg, unpublished data). ADAM21 is 
of interest because of the robust immunostaining in highly plastic areas: new adult 
primary olfactory neurons and their axons growing into the CNS, radial glial cells during 
postnatal development, and tanycyte-like cells in the in the adult subventricular zone 
where neurogenesis occurs (Yang et aI., 2005). ADAM21 has a catalytically active 
metalloproteinase (Hooft van Huijsduijnen, 1998). This evidence leads to the possibility 
that like its MMP relatives, ADAM21 could be involved in the processes which occur 
after spinal cord injury and contribute to secondary degeneration, repair, or plasticity. 
In the EAE model of demyelination, TIMP-1 deficient mice exhibited a delay in 
myelin formation which correlated with the decreased number of astrocytes found in the 
white matter (Crocker et aI., 2006, Moore et aI., 2011). Thus inhibition of 
metalloproteinases might result in increased spared white matter which would result in 
locomotor recovery following spinal cord injury. Additionally, CGRP can be induced by 
cytokines such as TNFa (Schafers et aI., 2003) resulting in hypersensitivity to non-
noxious stimuli (allodynia). Since several ADAMs have been linked to activation of 
TNFa, it is plausible that activation of TNFa or other pro-inflammatory cytokines could be 
a mechanism in which ADAM21 could have a role in pain development after spinal cord 
injury (Karkkainen et aI., 2000, Doedens et aI., 2003, Hooper et aI., 2005, Hikita et aI., 
2009, Pruessmeyer and Ludwig, 2009). Notch is another known target of ADAMs, in 
particular ADAM10 and possibly ADAM17, which requires shedding of its ectodomain 
before a second cleavage is required for release of Notch intracellular domain by y-
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secretase (Wen et aI., 1997, Qi et aI., 1999, Brou et aI., 2000, Mumm et aI., 2000, Deuss 
et aI., 2008). Modulations by metalloproteinases in Notch signaling following spinal cord 
injury could affect cell proliferation, angiogenesis, or transcription of proteins (Yamamoto 
et aI., 2001, Fassbender et aI., 2011 a). Lastly, ADAM21 's presence in radial glial cells, 
which could potentially act as neural stem cells in the adult spinal cord resulting in 
neuronal repair and regeneration after spinal cord injury. 
Here we investigated the functional outcomes after a T9 spinal cord injury in 
adult ADAM21-deficient mice by assessing locomotion, balance, and fine motor skills, as 
well as thermal nociception over a 6-week period. Additionally, we measured 
histological outcomes such as spared white matter, and the area occupied by CGRP and 
GFAP immunostaining at and around the injury epicenter. 
METHODS 
Animals 
A total of 55 mice were used, i.e., adult male and female littermates from each 
genotype were age and gender matched. They were bred in house from heterozygous 
B6.129P2-ADAM21tm1Dgen/J mice (stock# 006431, Jackson Laboratory, Bar Harbor, 
ME, USA; crossbred a minimum of 3 times with C57B/6 mice) and crossbred in house 2 
more times with C57B/6J mice (stock# 000664, Jackson). The deleted gene was 
replaced by a Lac-z containing cassette. The genotyping protocol was supplied by 
Jackson laboratory (refer to 
http://jaxmice.jax.org/protocolsdb/f?p=116:2:442721623684068::NO:2:P2_MASTER_PR 
OTOCOL_ID,P2_JRS_CODE:1256,006431). All animal procedures were performed 
according to University of Louisville Institutional Animal Care and Use Committee 
protocols and the National Institutes of Health guidelines. 
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Spinal cord injury 
Mice were anesthetized by an intraperitoneal injection of 0.4 mg/g body weight 
Avertin (2,2,2-tribromoethanol in 0.02 ml of 1.25% 2-methyl-2-butanol in saline, Sigma-
Aldrich, St Louis, MO). A 50 kdyn T9 contusion injury was made using an Infinite 
Horizons (IH; Precision Systems and Instrumentation, LLC, Lexington, KY) impactor 
after a laminectomy was made at T9 spine level. Sham animals received the same 
treatment as injured animals short of the impact on the spinal cord. All animals received 
subcutaneous injection of 2 ml saline (1 ml before and after injury) and 0.1 ml of 
gentamicin (20 IJg/ml stock, ButlerSchein, Dublin, OH). Gentamicin was also given on 
day 2 and 4 post injury. Bacitracin ointment (Qualitest Pharmaceuticals, Huntsville, AI) 
was applied to the sutured wound area. Once animals were fully awake, twice-daily 
analgesia was administered subcutaneously for the first 48 hours of 0.1 ml of a 15 IJg/ml 
stock solution of buprenorphin (Reckitt Benckise, Hull, England). Animals were placed 5 
per cage on Alfa Dry bedding and recovered on a water circulating heating pad 
overnight. Animal bladders were manually voided, as needed, once or twice daily until 
automatic voiding returned spontaneously, usually within 7-10 days. Metal sutures were 
removed between 7 and 10 days post injury. As in indicator of overall health and growth 
of the animals, the weight was checked prior to and after injury. Animals from each 
group continually gained weight and no significantly different weight gain was observed 
between genotypes. 
BMS analyses 
Mice were tested for hindlimb locomotor function before injury to establish a 
baseline, and weekly after injury beginning at 7 days using the Basso Mouse Scale 
(BMS) (Basso et aI., 2006). Animals were place in a 47-inch metal pool and observed 
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for 4 minutes by two trained individuals who were blinded to genotype and injury. Only 
individuals certified by Dr. Michelle Basso at Ohio State University were used in the 
behavior testing. Animals were given a score ranging from 0 to 9, with a score of zero 
having no movement of the hindlimbs and 9 signifying a normal animal with proper 
hindlimb coordination, trunk stability, paw placement, and tail position. Animals with a 
score of greater than or equal to 5 received a subscore ranging from 0 to 11. 
Beam Walk analyses 
The balance and fine motor skills were tested at baseline and weekly after injury 
using a graded series of suspended on 47 cm long metal beams of various widths: 4mm, 
8mm, 12mm, 16mm, and 20mm, which was modified from the previously described 
beam walk method (Hill et aI., 2009). In short, the narrowest beam a mouse could walk 
across was used for testing. The animals were scored based on beam size and the 
number of errors while crossing the beam. The final score was obtained by averaging 
the scores of two trials obtained on smallest crossable beam for each animal. Details of 
the scoring sheet are described elsewhere (Hill et aI., 2009). 
Hargreaves analyses 
Thermal nociception thresholds in mouse forepaws and hindpaws were 
evaluated using a Hargreaves device (IITC 390 Plantar Test; IITC Life Sciences, CA). 
The intensity of the heat source was set at 30%. The mice were placed in a Plexiglas 
testing chambers with a glass floor that was maintained at 3rC. The mice were allowed 
to acclimate to the apparatus for twenty minutes. The radiant heat source was placed 
alternately under the plantar surface of each forepaw and hindpaw until the animal 
withdrew its paw from the stimulus. The latency time was recorded for each forepaw 
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and hindpaw. There was a cutoff time of twenty seconds in order to avoid tissue 
damage. At each time point, testing was repeated five times per animal with a minimum 
of 5 minutes between each trial. The latency of withdrawal for each paw was averaged. 
Mice were tested before injury to establish at baseline and after injury weekly beginning 
at 7 days. 
Tail Flick 
Thermal nociception thresholds in the mouse tail was evaluated using Tail Flick 
Analgesia Meter (Columbus Instruments, Columbus, OH) with the intensity set at 6 
resulting in a baseline of around a 2 second withdrawal time. Mice were restrained in 
the Tailveiner (TV-150, Braintree Scientific, Braintree, MA) and the tail was placed in the 
groove with a shuddered light. Once the shutter was turned off, the tail-flick response 
was measured using automatic detection. The trial was repeated 3 times for each 
animal with no less than 5 minutes between trials. Mice were tested at baseline and 
weekly after injury. 
Histology 
Mice were anesthetized and transcardially perfused with 20 ml of ice-cold PBS, 
pH 7.4, and 10 ml of ice-cold 4% paraformaldehyde in 0.1 M phosphate buffer. 
Afterwards, a 1 cm segment of the spinal cords was carefully dissected out, post-fixed in 
4% paraformaldehyde overnight, and subsequently stored in Millonigs solution. Before 
freezing, the spinal cord segments were cryoprotected in 30% sucrose in 0.1 M 
phosphate buffer overnight followed by embedding in Tissue Freezing Medium (TFM-C, 
Triangle Biomedical Sciences, Durham, NC). Twenty consecutive transverse 20 J.Jm 
sections per 1 mm were cut on a cryostat, mounted on charged microscope slides, and 
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stored at -20°C until staining. Additionally, the spinal cords of a group of na"ive animals 
from each genotype was also cut in 20 IJm sections from T7 to T11 and every section 
was collected. One in every 10 sections from the na·ive spinal cords was used for 
staining. 
A modified eriochrome cyanine staining protocol was used to detect white matter 
tracts. Briefly, one in every 5 sections was thawed for 1 hour at 3rC, immersed in 
xylene (2 x 30 minutes), followed by a graded alcohol series ( 3 min 100% EtOH, 3 min 
70% EtOH, 3 min 50% EtOH, 2 min dH20), 10 minutes in eriochrome cyanine reaction 
RC stain (0.16% eriochrome cyanine RC in 0.4 FeCI3 and 0.4% H2S04), rinsed twice in 
tap water, differentiated for 30 seconds in 0.5% NH40H, rinsed twice in tap water to stop 
differentiation, and allowed to dry overnight at room temperature. Slides were then 
placed in xylene for 10 minutes and cover slipped using Permount (SP15, Thermo 
Fisher Scientific, Pittsburg, PAl. The area of most myelin loss was used to determine 
the epicenter by calculating total number of pixel stained using manual threshold in 
ImageJ software (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, 
Maryland, http://imagej.nih.gov/ij/, 1997-2011.) 
Adjacent sections were stained for GFAP, CGRP, j3-galactosidase (from the Lac-
z reporter gene), and ADAM21. Sections were thawed for one hour and the dried Tissue 
Freezing Medium was carefully removed with forceps. In short, the sections on the 
slides were circled with a hydrophobic barrier using a Super PAP Pen (Cat.# 008899, 
Invitrogen, Carlsbad, CAl, rinsed twice with 0.1 M Tris-Buffered Saline containing 0.3% 
Triton-X (TBS-Tr), incubated 1 hr in 5% donkey serum in TBS-Tr at room temperature, 
incubated overnight in 4°C primary antibody containing 5% donkey serum in TBS-Tr and 
mouse anti-GFAP (1 :1000, Cat.# MAB3402, clone GAS, Millipore, Billerica, MA), rabbit 
anti GFAP (Cat.# Z0334, Dako, Carpinteria, CAl, rabbit anti-CGRP (1 :1000, Cat.#, 
Millipore, Billerica, MA), mouse anti-j3-galactosidase (Cat.# 23781, Promega, Madison, 
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WI), or rabbit anti-AOAM21 (1 :1000, Cat.# AB19001, Millipore, Billerica, MA). Next, the 
slides were rinsed 3 times in 0.1 M Tris-Buffered Saline (TBS), incubated for one hour 
containing 5% donkey serum in TBS at room temperature with donkey anti-mouse or 
donkey anti-rabbit secondary Alexa Fluor antibody (1 :200, Cat.# A-21202, A-21203, and 
A-21206, Invitrogen, Carlsbad, CA), rinsed 3 times in TBS, and cover slipped using 
Fluormount (Cat.# 0100-01, Southern Biotech, Birmingham, Alabama). Images for 
analysis were taken with a 10x objective for eriochrome cyanine staining and GFAP 
immunostaining and a 20x objective for CGRP immunostaining on a OM 6000 Leica 
upright microscope using the automated stitching Surveyor software (Objective Imaging, 
Cambridge, UK) in conjunction with an Oasis Automation Controller (Objective Imaging, 
Cambridge, UK) which drives the motorized stage. CGRP images from the second 
series of naive mice were taken using a z-stack of 15 !-1m with a 5 !-1m step. 
Histology image analysis 
The total number of pixels of spared white matter visualized byeriochrome 
cyanine staining and GFAP immunostaining was calculated using manual threshold in 
ImageJ (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, 
Maryland, USA, http://imagej.nih.gov/ij/, 1997-2011.) Fast Fourier Transform (FFT) 
using Image Pro Plus software (version 6.2, Media Cybernetics, Inc, Bethesda, MO) was 
used on injured spinal cords that were immunostained with CGRP. In short, pictures 
were converted to monochrome, followed by FFT with a spectrum gain of 70 and an 
area of interest (AOI) of an ellipse radius of 5,5 which corresponds to 1638 pixels per 
period. Frequencies within the radius were cut. Then an inverse FFT was applied to the 
original image reducing the signal to noise ratio. Then the total number of pixels was 
calculated using the manual threshold in ImageJ. The AOI, dorsal horn of the spinal 
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cord was boxed with two boxes (2500px x 2500px) originating at the central canal and 
extending across each dorsal horn was drawn. The na·ive spinal cords were analyzed 
using the same method as the spinal cord injured with the exception of the Fourier 
transformation. The two sets of tissue analyzed for CGRP immunostaining, spinal cord 
injured and na·ive, were not stained at the same time or analyzed by the same person. 
The three-fold difference in total stained area is most likely due to higher signal of CGRP 
labeling. All sections within a group were analyzed by the same person to decrease 
variability. 
Statistical analysis 
A repeated measure ANOVA over time with covariate analysis on gender, age, 
and weight with a paired Student's post-hoc t-test was used to determine significance in 
all behavior data. For histological data, an unpaired Student's t-test was performed 
between genotypes. A value of p :s; 0.05 was considered statistically significant. All 
values are reported with standard error of the mean. 
RESULTS 
ADAM21 localization 
ADAM21 immunostaining in uninjured wildtype adult mice was found in laminae I 
and II of the dorsal horns of the spinal cord (Figure BA and 8), the region of nociceptive 
innervation, and in the ependymal cells around the central canal (Inset of Figure B8). 
Similar to the wildtype mice, ADAM21 immunostaining is present in ADAM21-deficient 
mice in the dorsal horns (Figure BD and E) and in the ependymal cells surrounding the 
central canal (Inset of Figure BE). The ADAM21-deficient mice contain a LacZ reporter 
gene within the insertion cassette enabling localization of ADAM21 expression by 
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immunostaining for its ~-Galactosidase (~-Gal) protein product. As expected, no 
immunostaining was present in the spinal cords of wildtype mice (Figure SC). In the 
sham or na"lve ADAM21-deficient mice, ~-Gal immunostaining was present in tube-like 
structures that appeared to be associated with blood vessels (Figure SF, G and H; 
indicated by arrow in G and H). In the injured spinal cord, the ~-Gal immunostaining was 
occasionally seen in cells with a single leading process similar to a migrating cell were 
seen in the white matter (Figure SI). In addition, ~-Gal immunostaining appeared in cells 
with morphology similar to microglia at the epicenter, rostral, and caudal to injury site 
(Figure SJ). 
Surprisingly, the ~-Gal immunostaining in the ADAM21-deficient spinal cords did 
not show the same pattern as seen with the ADAM21 antibody in na"lve or injured spinal 
cords (Figure SA, B, D, and E). Coupled with ADAM21 immunostaining in the ADAM21-
deficient mice and lack of co-labeling with the ~-Gal reporter gene, leads us to believe 
the ADAM21 immunostaining in which our original hypothesis was based from does not 
detect ADAM21 protein. 
Behavioral comparison between ADAM21-deficient and wildtype mice. 
As expected, 1 week after spinal cord injury there was a significant decrease in 
the BMS scores in both ADAM21-deficient and wildtype animals that remained 
significantly different from baseline 6 weeks after injury (Table 1). However, there was 
not a significant difference between these two groups at any time over the 6 weeks 
following the spinal cord injury. Of note, BMS scores are higher than normally seen due 
to mild injury indicated by the low displacement values of the animals in this study. 
Likewise, Beam walk had a significant decrease in scores 1 week following spinal cord 
injury in both genotypes and remained significantly different over the 6 weeks following 
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the injury (Table 1). ADAM21-deficient mice did not gain additional gross or fine 
locomotor function beyond the spontaneous recovery consistently seen in mice. 
At 1 week post injury, there was a significant drop in withdrawal time following 
thermal stimuli; however, no significant differences was found between ADAM21-
deficient and wildtype mice prior or after spinal cord injury in the Hargreaves test on the 
hind paws (Table 1). Tail Flick did not show any differences between genotypes or within 
a genotype from baseline at any time over the 6 weeks following injury (Table 1). The 
decrease in hindpaw withdrawal time indicts hypersensitivity following spinal cord injury 
in both ADAM21-deficient and wildtype mice. 
Epicenter histology: comparison between ADAM21-deficient and wildtype mice. 
The area of white matter sparing was assessed by eriochrome cyanine staining. 
There was no significant difference between the spared white matter in ADAM21-
deficient compared to wildtype animals at the injury epicenter, 1 mm rostral, 1 mm 
caudal or the total penumbra (1 mm rostral and caudal combined) to the injury (Table 2). 
In both genotypes the amount of spared white matter was approximately 50% of sham 
which is consistent with the relatively high BMS scores, indicating a mild injury. 
CGRP immunostaining was evaluated in order to investigate the possibility of 
ADAM21 induced sprouting in the dorsal horns. At the epicenter, CGRP was decreased 
significantly from the penumbra probably due to the loss of neurons at the compression 
site shortly after injury. The total area of CGRP immunostaining was not found to be 
significantly different after injury between ADAM21-deficient and wildtype mice at 
epicenter, 1 mm rostral, 1 mm caudal, or total penumbra (Table 2). Although the degree 
of CGRP staining extending past Laminae II was not quantified, there were no obvious 
indications of sprouting in either genotype. The difference of the CGRP immunostaining 
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in the sham animals could not be statistically analyzed due to the small sample size in 
the wildtype shams (n=2). The sample size was small due to unexpected deaths in the 
wildtype shams; in addition, additional wildtype shams were not available due to lack of 
extra wildtype littermates of ADAM21-deficient mice. The values in the sham-operated 
ADAM21 +/- mice were similar to those of the ADAM21-deficient mice (data not shown). 
GFAP increased significantly at the epicenter of the injury, as expected, due to 
the infiltration of glial cells and formation of the glial scar following spinal cord injury. 
However, the area of GFAP immunostaining was also not found to be significantly 
different between genotypes after injury or in the shams in the epicenter, 1 mm rostral, 1 
mm caudal, or the total penumbra (Table 2). Since there were only two sham-operated 
wildtype mice, we repeated the CGRP analysis on a new set of na'ive spinal cords using 
a more precise tissue section sampling method to eliminate variations due to the 
laddering effect seen in CGRP staining. In the na'ive spinal cords, there was no 
difference between genotypes in total area of CGRP immunostaining from T7 to T1 0, the 
area of the injury epicenter and penumbra of the other groups of mice (Table 3). This 
suggests that the CGRP values seen in the two sham-operated mice were artifactually 
low. 
DISCUSSION 
Surprisingly, J3-Gal, a reporter for ADAM21 protein in the ADAM21-deficient mice 
showed expression in the null mouse that had a different cellular distribution than was 
found with the ADAM21 antibody in wildtype mice. Since the ADAM21-deficient mice 
contain a LacZ reporter gene, we presume that the J3-galactosidase immunostaining 
shows the areas and cell types that produce ADAM21. From the J3-Gal immunostaining 
ADAM21 expression appears to be localized in blood vessels in the naIve animal and 
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activated microglia, and migrating neurons in the injured animal, although this remains to 
be verified by markers to co-labeling for blood vessels and microglia. However, the 
antibody staining of the dorsal horn and ependymal cells seems to be non-specific for 
the ADAM21 protein due to its presence in ADAM21-deficient mice and the lack of any 
colocalization with the reporter, ~-Gal. As mentioned in Chapter 4, a truncated ADAM21 
transcript is still present in the ADAM21-deficient mice. Since the ADAM21 antibody 
stained the last 13 amino acids of the protein, this in addition to the truncated ADAM21 
transcript could explain why there is immunostaining in the ADAM21-deficient mice. 
However, the only explanation for why the ~-Gal does not colabel with ADAM21 is that 
the ADAM21 antibody is not detecting the ADAM21 protein. This could explain the 
absence in a phenotype involving sprouting and pain development because it seems 
that ADAM21 is not localized in the dorsal horns. 
Originally, due to the location in the brain of ADAM21 antibody immunostaining in 
radial glial lineage cells in the SVZ and growing axons in the olfactory bulb, we believed 
that ADAM21 could regulate plasticity and subsequent pain development following spinal 
cord injury by regulation of cytokines such as TNFa or CX3CL which require ectodomain 
shedding for activation. The initiation of the inflammatory response is thought to 
originate with astrocytes following injury (Pineau et aI., 2010); astrocytes which are 
damaged or at the site of damage can release cytokines such as TNFa in response to 
the injury which explains the increase seen in TNFa at 1 hour following spinal cord injury 
(Harrington et aI., 2005, Peng et aI., 2006, Zhang et aI., 2011b). However, since the 
ADAM21 antibody is probably not an accurate depiction of cellular expression of 
ADAM21, this explains why our hypothesis was wrong. 
Here we evaluated the potential role of ADAM21 in the intact adult animal and 
after spinal cord injury using ADAM21-deficient mice. We found no differences between 
adult ADAM21-deficient mice and their littermates under normal or injury conditions in 
51 
locomotion and coordination, fine motor and balance or thermal nociception. The similar 
extent of white matter sparing between the genotypes is consistent with the similar BMS 
scores, as these two are known to correlate (Basso et aI., 2006, Han et aI., 2010). Our 
data from two different thermal nociception tests and the CGRP immunostaining argue 
against the possibility of ADAM21 being involved in sprouting and pain development. 
Since our original hypothesis suggested ADAM21 protein in radial glial cells we analyzed 
normal distribution of astrocytes and their responses to injury using GFAP 
immunostaining. However, there were no significant differences in the area of GFAP 
seen at the injury epicenter and penumbra between the ADAM21-deficient mice and 
their wildtype littermates. Thus, based on these results, ADAM21 does not seem to play 
a role in spinal cord development or in responses to injury during adulthood. One caveat 
to this conclusion is the fact that our injuries turned out mild, lacking clear signs of 
sensory sprouting. Therefore, it is possible that ADAM21 plays a role in more severe 
injuries, for example in the allodynia that develops. 
Similar to ADAM21, ADAM9 was found to be widely expressed in the brain and 
spinal cord, but no phenotype was found in development or in naIve adult ADAM9 
knockout animals (Weskamp et aI., 2002). In addition, ADAM8, a catalytically active 
metalloproteinase (Fourie et aI., 2003), has been implicated in the inflammatory 
response of asthma (King et aI., 2004, Dehmel et aI., 2007), but when knocked out there 
was no apparent phenotype either by defect or pathologically (Kelly et aI., 2005). 
However, when ADAM8 deficient were crossed with wobbler (WR) mice, double mutant 
had a more severe disease phenotype than ADAM8+/- WR mice and resulted in a 
dramatic decrease in survival (Bartsch et aI., 2010). The role of ADAM9 and ADAM8 
was not found to be essential for normal development or in adult mice; however, the role 
of ADAM8 was elucidated only after the cross with another mutant mouse. This is 
probably best highlighted in the case of ADAM9, ADAM12, ADAM15, ADAM17, and 
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ADAM19. ADAM12 and ADAM15 were found not to have overlapping roles in with 
ADAM9, ADAM17, and/or ADAM19 as combination of ADAM12 and/or ADAM15 did not 
increase the severity when combined with combinations of ADAM9, ADAM17 and/or 
ADAM19 lines (Horiuchi et aI., 2005). Through different combinations of the preceding 5 
ADAMs, it was discovered that ADAM9 and ADAM19 have compensatory or redundant 
roles (Horiuchi et aI., 2005). Similar to the ADAMs mentioned above, ADAM21 could 
have an overlapping or redundant role with another ADAM. In a separate study, we 
have not found any metalioprotease gene which solely compensates for the lack of 
ADAM21 before or after spinal cord injury in this mouse line (Chapter 4). However, this 
does not preclude the possibility of redundancy across several ADAMs causing the 
deletion of ADAM21 to show no evident pathological phenotype. 
In conclusion, it seems that ADAM21 does not play an essential role in the 
development of the mouse, as is the case with ADAM 10 and ADAM 17 or essential in the 
recovery after spinal cord injury. However, the function of ADAM21 may be revealed 
through combining the ADAM21-deficient line with that of another ADAM deficient line 
like was seen with other ADAM deficient mouse lines or by using a different outcome 
measure that was not covered in this study. Alternatively, ADAM21 might have both 
beneficial and detrimental roles after spinal cord injury which results in the neutral 
phenotype of the ADAM21-deficient mice. 
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Naive KO Injured KO 
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Figure 8. ADAM21 and f3-Galactosidase immunostaining in the adult spinal cord in 
sham and spinal cord injured mice. 
Transverse sections of the mouse spinal cord were stained with ADAM21 antibody. 
ADAM21 immunostaining of the intact spinal cord of wildtype (WT) (A and 8) and 
ADAM21-deficient (KO) mouse (D and E): punctated immunostaining is present in the 
dorsal horn of wildtype mouse and ADAM21-deficient mouse. Labeling in the 
ependymal cells of the central canal is present in wildtype and ADAM21-deficient 
mouse, Inset of Band E, respectively. B-Galactosidase immunostaining in the intact 
spinal cord of wildtype (WT) (C) and ADAM21-deficient (KO) mouse (F) . 13- Gal 
immunostaining in the intact cord shows vessel-like structures (G and H) and in the 
injured spinal cord of ADAM21 deficient mice shows possible microglial cell in the white 
matter (I and J). WT = wildtype mouse and KO = ADAM21 deficient mouse. Scale bars 
for A, C, D and F, shown in A, represents 20 IJm, for Band E, shown in, represents 20 
IJm, and for G-J , shown in G, represents 5 IJm. 
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BMS Beam Walk Hargreaves Tall Flick 
(sec) (sec) 
Baseline 9.0 ± 0.00 24.8 ± 0.09 3.43 ± 0.29 1.92 ± 0.08 
Week 1 4.9 ± 0.45 4.7 ± 1.34 2.36 ± 0.20 1.86 ± 0.10 
Week 2 6.0 ± 0.50 7.5 ± 1.36 2.73 ± 0.22 1.69 ± 0.07 
+ Week 3 7.3 ± 0.37 9.3 ± 1.30 2.62 ± 0.17 1.69 ± 0.07 -+ 
Week 4 6.7 ± 0.34 10.6 ± 1.34 2.89 ± 0.27 1.91 ± 0.11 
Week 5 7.1 ± 0.31 11.8 ± 1.77 2.86 ± 0.13 1.78 ± 0.09 
Week 6 6.9 ± 0.33 11.2 ± 1.55 2.94 ± 0.23 1.84 ± 0.12 
Baseline 8.9 ± 0.08 24.6 ± 0.28 3.58 ± 0.29 1.79 ± 0.08 
Week 1 6.1 ± 0.81 5.4 ± 1.68 2.59 ± 0.17 1.82 ± 0.07 
Week 2 6.9 ± 0.68 9.2 ± 1.88 2.83 ± 0.15 1.81±0.16 
I 
Week 3 7.1 ± 0.56 11.4 ± 1.54 2.72 ± 0.15 1.78 ±0.10 .,. 
Week 4 7.4 ± 0.49 11.8±2.05 2.62 ± 0.17 1.85 ± 0.16 
Week 5 6.8 ± 0.42 12.6 ± 1.91 2.60 ± 0.14 1.63 ± 0.10 
Week 6 7.2 ± 0.47 12.2 ± 1.94 2.85 ± 0.24 2.06 ± 0.10 
Table 1. Behavioral assessments between ADAM21-deficient mice and wi/dtype 
littermates. 
There is no statistical significant difference between wildtype and ADAM21-deficient 
mice in BMS, Beam Walk, Hargreaves, and Tail Flick. Weeks 1-6 in both wildtype and 
ADAM21-deficient mice are significantly different from baseline for BMS, Beam Walk, 
and Hargreaves. Scores for BMS and Beam walk in arbitrary units ± SEM and scores 
for Hargreaves and Tail Flick are in seconds ± SEM. n =13 and 10 for injured wildtype, 
and injured ADAM21-deficient, respectively. Data for shams is not shown. n = 2 and 3 
for wildtype and ADAM21-deficient, respectively. 
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Sham Injured 
+1+* -/- +/+ -/-
"gCl"'- Rostral1rrrn 1.07 1.16±0.071 0.81 ± 0.031 0.85 ± 0.036 _Cl'E .... - ::: Epicenter 1.16 1.11 ± 0.064 0.53 ± 0.042 0.59 ± 0.042 I'll .c I'll E 
~~ ~ -- Caudal1rrrn 1.02 1.09 ± 0.057 0.81 ± 0.035 0.81 ± 0.053 
Rostral + Caudal 1.05 1.13±0.044 0.81 ± 0.023 0.83 ± 0.032 
0.--
Rostral1rrrn 59,737 56,187 ± 7,200 129,583 ± 13,644 128,803 ± 14,999 
c(N Epicenter 34,182 62,772 ± 5,180 211,638 ± 20,168 219,102 ± 18,387 u.. E 
(!).:: Caudal 1 rrrn 41,409 64,491 ± 18,496 111,492 ± 12,620 116,925 ± 15,406 
Rostral + Caudal 50,573 60,339 ± 9,068 120,538 ± 9,283 122,551 ± 8,715 
Rostral1rrrn 976 5,062 ± 634 2,964 ± 356 3,753 ± 555 
0.-
Epicenter 960 4,774 ± 788 2,208 ± 1,050 2.742 ± 362 o::N 
(!) E Caudal 1 rrrn 1,644 4,452 ± 920 3,086 ± 460 3,588 ±474 u':: 
Rostral + Caudal 1,310 4.757 ± 518 3,017 ± 277 3,679 ± 363 
Table 2. Histological analyses. 
There was no difference between wildtype and ADAM21-deficient mice in spared white 
matter, GFAP, and CGRP. The epicenter of injured within each genotype was 
significantly different from 1 mm Rostral, 1 mm Caudal, and penumbra (1 mm Rostral + 
1 mm Caudal) in all 3 analyses. White matter sparing is in mm2 and GFAP and CGRP 
are in IJm2 ± SEM with the exception of wildtype sham due low number of animals. n = 





T7 13,438 ± 2,980 
T8 14,626 ± 2,708 
T9 14,550 ± 2,677 
T10 15,532 ± 2,559 
n= 4 
-/-
14,662 ± 963 
15,539 ± 1,968 
14,622 ± 1,568 
13,706 ± 2,074 
4 
Table 3, CGRP immunostaining in naiVe ADAM21-deficient and wiJdtype littermates. 
Na"lve levels of CGRP were analyzed to confirm no differences of CGRP at basal levels. 
There was no significant difference between wildtype and ADAM21-deficient animals at 
T7 through T10. All values are given in IJm2 ± SEM. n=4 in all groups. 
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CHAPTER FOUR 
COMPREHENSIVE AND QUANTITATIVE METALLOPROTEINASE 
GENE ANALYSES REVEAL A REGULATORY ROLE OF ADAM21 IN 
NORMAL AND INJURED MOUSE SPINAL CORD 
INTRODUCTION 
The ADAM proteins belong to the adamalysin family of the metzincin or zinc-
dependent metalloproteinase superfamily which also includes the MMPs. ADAMs have 
a disintegrin and metalloproteinase domain, as well as cysteine-rich, EGF-like module, 
transmembrane and cytoplasmic signaling domains (Wolfsberg et aI., 1995, Yang et aI., 
2006). The adamalysin subfamilies also include the ADAMTS (containing a 
thrombospondin repeat and lacking the EGF-like, transmembrane, and cytoplasmic 
domains) and ADAMTSL (lacking the pro-metalloproteinase and disintegrin-like 
domains) (Tang and Hong, 1999, Apte, 2009). The catalytic activity of all the 
metalloproteinases is inhibited by tissue inhibitors of metalloproteinases (TIMPs) (Brew 
and Nagase, 2010). 
ADAMs are best known for their role as sheddases in activating cleavage-
dependent membrane proteins such as Notch and TNFa (Reiss and Saftig, 2009). 
MMPs and secreted ADAMTS proteins are best known for extracellular matrix digestion 
during tissue remodeling, process outgrowth, and cell migration (Pilcher et aI., 1999, 
Curry and Smith, 2006, Amalinei et aI., 2007, Ihara and Nishiwaki, 2007). Another 
unique feature of ADAMs is the disintegrin domain which binds integrins (Bigler et aI., 
2000, Evans, 2001). Little is known about the mechanism of action or function of all but 
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a few metalloproteinases in general or specifically in the nervous system (Yang et aI., 
2006, Yong et aI., 2007). Several ADAMs have been associated with diseases or 
disease pathology such as asthma/inflammation (Van Eerdewegh et aI., 2002, Booth et 
aI., 2007, Koller et aI., 2009, Mukhopadhyay et aI., 2010) and neurological diseases 
(Gerst et aI., 2000, Barrette et aI., 2010). 
In the injured spinal cord, MMP2 and MMP9 were found to be acutely up 
regulated in blood vessels, macrophages and astrocytes and to playa predominantly 
detrimental role (de Castro et aI., 2000, Noble et aI., 2002, Goussev et aI., 2003, Hsu et 
aI., 2006, Zhang et aI., 2011a). Increased MMP12 expression by microglia has a 
detrimental role as shown in injured MMP12-/- mice (Wells et aI., 2003). Increased 
ADAM8 expression is exclusively localized to endothelial cells after spinal cord injury 
and possibly has a role in angiogenesis (Mahoney et aI., 2009). In humans, MMP1, 
MMP2, MMP9, and MMP12 are expressed in response to spinal cord injury (Buss et aI., 
2007). Previously, changes in 22 MMPs have been documented up to 5 days following 
compression injury in adult mice (Wells et aI., 2003). Others performed an Affymetrix 
gene array analysis after a contusive spinal cord injury in adult mice (GEO Profiles 
accession GDS2159) which did not include all metalloproteinases and was not 
quantitative or verified. 
We have shown robust ADAM21 immunostaining in continuously generated 
primary olfactory neurons and their growing olfactory bulb axons, as well as in radial glial 
lineage cells in the neurogenic subventricular zone of adult mice (Yang et aI., 2005). Its 
localization in highly plastic areas of the adult CNS raised the possibility that ADAM21 
might play an orchestrating role in repair processes after spinal cord injury. ADAMs 
could regulate expression of other metalloproteinases for example through activation of 
the Notch or TNFa pathways (Samuel et aI., 2005, Jie et aI., 2009, Bartsch et aI., 2010, 
Li et aI., 2011). 
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Here, we used a focused comprehensive quantitative Real-Time RT-PCR 
(qPCR) gene microarray to document changes in ADAM, ADAMTS, MMP, and TIMP 
expression following a contusive spinal cord injury in adult mice. We also determined 
the potential role of ADAM21 in regulating other metalloproteinases under normal and 
injury conditions using ADAM21 wildtype and homozygous ADAM21-deficient 
littermates. 
MATERIAL AND METHODS 
Animals 
A total of 40 mice were used, i.e., adult male and female homozygous ADAM21-
deficient and wildtype littermates were age and gender matched. They were bred in 
house from heterozygous B6.129P2-ADAM21tm1 Dgen/J mice (stock# 006431, Jackson 
Laboratory, Bar Harbor, ME, USA; crossbred twice with CS7B/6 mice) and crossbred in 
house 3 more times with CS7B/6J mice (stock# 000664, Jackson). The B6.129P2-
ADAM21tm1Dgen/J (ADAM21-deficient) mouse line was produced by Deltagen, Inc. 
which performed a preliminary characterization showing no overt phenotype in multiple 
organs and physiological measurements 
(http://www.informatics.jax.org/external/ko/deltagen/142.html). All animal procedures 
were performed according to University of Louisville Institutional Animal Care and Use 
Committee protocols and the National Institutes of Health guidelines. 
Spinal cord injury 
Mice were anesthetized by an intraperitoneal injection of 0.4 mg/g body weight 
Avertin (2,2,2-tribromoethanol in 0.02 ml of 1.2S% 2-methyl-2-butanol in saline, Sigma-
Aldrich, St Louis, MO, USA). A laminectomy was made at T9-T10 spine level and a SO 
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kdyn T9 contusion injury was made using an Infinite Horizons (IH) impactor with steel 
stabilizers inserted under the transverse processes one vertebra above and below the 
injury in order to stabilize the spine. Sham animals received a T9-T1 0 laminectomy only. 
Animals received 0.1 ml of a 20 j.Jg/ml stock of gentamicin (ButlerSchein, Dublin, OH) 
and 2 ml saline injected subcutaneously (1 ml before and after injury). After the wound 
was sutured in layers, Bacitracin ointment (Qualitest Pharmaceuticals, Huntsville, AI) 
was applied to the wound area and the animals recovered on a water circulating heating 
pad. Analgesics were given twice daily for first 48 hours of 0.1 ml of a 15 j.Jg/ml stock 
solution of buprenorphin (Reckitt Benckise, Hull, England). Analgesia was only given 
after the animal was fully awake due to a lethal interaction with Avertin. Manual bladder 
expression occurred, as needed, once or twice daily until automatic voiding returned 
spontaneously, usually within 7-10 days. 
BMS analyses 
The mice were tested for hindlimb locomotor function before injury to establish a 
baseline, and at 7 days, and 14 days post-injury using the Basso Mouse Scale (BMS) 
(Basso et aI., 2006). In short, two people trained and certified by Michelle Basso at 
Ohio State University observed mice for 4 minutes in a 47-inch diameter dry pool. The 
scores range from 0 - 9, where 0 is completely paralyzed and 9 being normal 
coordination, paw placement, truck stability and tail up. Subscores are given when the 
animals reach 5 and above on the BMS scale. 
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Tissue collection and mRNA measurements by quantitative Real-Time reverse 
transcription-PCR (qPCR) 
On the day of tissue collection, animals were anesthetized and perfused with ice-
cold PBS. A 4 mm section of spinal cord containing the injury epicenter was freshly 
dissected out and flash frozen using liquid nitrogen until further processing. Total RNA 
was isolated using a commercial kit (Cat #: AM1924, Ambion, Austin, TX). In short, 1 I-Ig 
of DNAse was added to RNA (Cat #: 18068-015, Invitrogen, Carlsbad, CA) and used as 
templates for reverse transcription, which included 1 1-11 of a 0.5 1-1 g/I-I I random primers 
(Cat# : C 1181 ,Promega, Madison, WI), 1 I-Ig total RNA, 5 1-11 of 5x buffer, 1.25 1-11 of 10 
mM dNTP mix, 2.25 1-11 RNAse free water, and 1 1-11 (200 units) of Moloney Murine 
Leukemia Virus Reverse Transcription (M-MLV RT, Cat #: M170, Promega, Madison, 
WI) and heated at 3rC for 1 hr. The qPCR was performed using TaqMan® Universal 
PCR Master Mix (Part Number: 4304437), TaqMan® Array Micro Fluidic Cards, Format 
96-a (Part Number: 4342259) and primer sets (see Table 4) from Applied Biosystems, 
Carlsbad, CA. All cards were run on an Applied Biosystems® 7900HT Fast Real-Time 
PCR System. Data was analyzed using the SDS 2.1 Relative Quantification software by 
the MCT/comparative CT method. All samples were normalized to GAPDH; sham 
spinal cord CT values of the same genotype were used as the calibrator. Statistical 
analyses were performed with the Student's unpaired t-test using Excel software for 
ADAM21-deficient sham versus wildtype sham (Microsoft, Redmond, WA). For all other 
comparisons, two-way ANOVA with Tukey post-hoc was used to compare genotype and 
changes over time. A value of p S 0.05 was considered statistically significant. 
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Housekeeping genes and negative control 
There were 4 housekeeping genes included on the qPCR array. They included 
hypoxanthine phosphoribosyl transferase 1 '(Hprt1), Beta-glucuronidase (Gusb), 
Glyceraldehyde 3-phosphate dehydrogenase (GapDH), and 1BS ribosomal RNA (1BS). 
Of these housekeeping genes, only two had steady CT values among all samples: 
GapDH and 1BS. However, GapDH was the least variable after spinal cord injury at 7 
and 14 days and thus used for normalization. In addition, our negative control for the 
qPCR array was human CNTF and was undetectable on all arrays. 
RESULTS 
Temporal mRNA profile in wildtype littermates after spinal cord injury 
Major changes (more than two-fold) in gene expression profile occurred in 19 
metalloproteinase genes following spinal cord injury in wildtype mice (Figure 9; Table 5). 
Seventeen metalloproteinases were increased more than two-fold at 7 and/or 14 days. 
Of these, ADAMB, ADAM33, and MMP12 were up regulated more than 10-fold 
compared to the uninjured sham mice at either or both day 7 and 14 post-injury. Only 3 
genes were decreased more than two-fold following injury, i.e., ADAM23, ADAMTS17, 
and MMP17. Surprisingly, ADAM21 was not detectable using the Mm01309314_m1 
assay which spans exon1 and exon2. However, in a separate qPCR analysis of the 
same RNA ADAM21 was detectable using the Mm004B0375_s1 assay which measures 
onlyexon2. There was no change in the expression level of ADAM21 after injury. 
We also measured expression levels of the 4 known endogenous 
metalloproteinase inhibitors. Only TIMP1 expression changed more than two-fold, 
increasing by almost 20-fold following spinal cord injury compared to sham. Also 
included were a few potential substrates of ADAMs to support future investigations into 
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their potential interactions. Thus, as expected, TNFa was highly up regulated at 7 and 
14 days after injury. Alpha-2 macroglobulin (A2m) was also increased at 14 days 
whereas alpha-synuclein (SNCA) showed a large decrease at 7 and 14 days post-injury 
compared to sham. Alpha-1 antitrypsin (Serpina1e) was not detectable in either sham or 
injured spinal cord. 
Sham-operated ADAM21-deficient mice have few changes compared to wild-type 
littermates 
Under normal conditions, only one gene, ADAMTS16, was significantly higher 
(1.7 fold) in ADAM21-deficient than in wild-type littermates. However, 4 genes, 
ADAM19, MMP17, MMP24, and TIMP4 were found to be significantly decreased in the 
ADAM21-deficient sham-operated mice. 
Surprisingly, ADAM21-deficient mice had an ADAM21 transcript detectable by 
the Mm00480375_s1 assay (beyond the deletion-insertion locus) which was confirmed 
by endpoint PCR of different regions of the 3' ADAM21 transcript (data not shown). This 
transcript was increased 3-fold in sham animals. However, we confirmed that the 
LacZ/Neo cassette was inserted into the ADAM21 gene in the middle of the 
metalioproteinase domain and prior to the catalytic site (data not shown). A theoretical 
in-frame ADAM21 start codon would make this a metalioprotease-nuli aberrant 
transcript. 
ADAM21-deficient mice have reduced expression levels of metalloproteinases 
after spinal cord injury 
In ADAM21-deficient mice, mRNA levels of 4 metalioproteinase genes, ADAM8, 
ADAM33, ADAMTS14, and MMP12 were more than 2 fold lower than their wildtype 
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littermates following spinal cord injury. Of these, ADAM8, ADAM33, and MMMP12, were 
decreased by more than 10 fold compared to their injured wild-type littermates. Two 
metalloproteinase genes (MMP10, MMP27) were detected at all time points in ADAM21-
deficient mice, but not detectable at any time point of their wild-type littermates. 
ADAM28 expression was not seen in wild-type mice, even after spinal cord injury but 
was seen in some sham-operated ADAM21-deficient mice (4 out of 7) and some injured 
mice after 14 days (2 out of 6). 
TIMP expression levels were not found to be different in injured ADAM21-
deficient mice. Of the metalloproteinase substrates measured here, only TNFa had 
expression levels more than two fold different in injured ADAM21-deficient mice 
compared to injured wild-type littermates. In fact, TNFa expression levels in the injured 
ADAM21-deficient mice were 10-fold less than that seen in injured wild-type mice. 
Only 8 metalloproteinase genes had no detectable expression in sham or injured 
mice irrespective of the presence or absence of ADAM21 or spinal cord injury. These 
included ADAM2, ADAM26b, ADAM34, ADAM36, MMP1a, MMP1b, MMP20, and 
MMP21. There were 15 metalloproteinases present in only a few samples and therefore 
could not be statistically analyzed in this array. These included ADAM3, ADAM5, 
ADAM6A1ADAM6B, ADAM7, ADAM24, ADAM25, ADAM26A, ADAM28, ADAM29, 
ADAM30, ADAM38, ADAM39, ADAMDEC1, ADAMTS13, and MMP7. 
Locomotor function 
As expected for a moderate injury, the BMS scores in the wildtype mice decreased to 
4.1 and 3.7 at 7 and 14 days post injury, respectively. Despite the striking differences in 
gene expression levels, there were no significant differences between genotypes in the 
baseline or post-surgery BMS scores of sham-operated mice or after a T9 contusive 
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spinal cord injury at 7 or 14 days (Figure 10). Additionally, at 14 days post-injury only 3 
out of 13 mice had high enough BMS scores to have a subscore, 2 of 7 animals were 
wildtype, and 1 of 6 was an ADAM21-deficient mouse which was not significantly 
different. 
DISCUSSION 
The ADAM21-deficient mouse results suggest that ADAM21 normally up-
regulates the expression of a substantial number of metalloproteinase genes following 
spinal cord injury. This is somewhat surprising as one of the greatest hurdles using 
knockout mice is the frequent redundancy or overlap of function between proteins due to 
their high homology within the domain structures and sheer number of 
metalloproteinases. Thus, we propose that ADAM21 is an important regulator after 
spinal cord injury. Of particular interest, a cluster of genes known for their role in 
inflammation (ADAM8, ADAM12, ADAM33, MMP12, TNFa (King et aL, 2004, Dehmel et 
aL, 2007, Jie et aL, 2009, Koller et aL, 2009, Mukhopadhyay et aL, 2010, Parameswaran 
and Patial, 2010)), exhibited a robust increase in injured wild type littermates, which was 
significantly attenuated in injured ADAM21-deficient mice. In addition, ADAM8, 
ADAM12, and ADAM33 are within the same phylogenetic group (Hooper et aL, 2005). 
This inflammatory gene cluster seems unique in that ADAM8, ADAM12, ADAM33, 
MMP12, and TNFa are the only ones so far that have been linked to asthma (Shapiro 
and Owen, 2002, Van Eerdewegh et aL, 2002, Holgate et aL, 2004, Haitchi et aL, 2005, 
Berry et aL, 2007, Koller et aL, 2009, Holgate, 2010, Mukhopadhyay et aL, 2010, 
Paulissen et aL, 2011). Under normal conditions (sham-operated), these genes were 
not changed in ADAM21-deficient mice. This raises the possibility that ADAM21 plays a 
central role in inflammatory responses under pathological conditions. However, only 6 
66 
papers have been published so far on ADAM21 (Hooft van Huijsduijnen, 1998, 
Poindexter et aL, 1999, Liu and Smith, 2000, Seldin et aL, 2000, Yang et aL, 2005, Yi et 
aL, 2010), mostly describing its presence in the testis, and its functional roles in different 
organs remains to be investigated. 
It remains to be determined how ADAM21 would regulate the expression of the 
other metalloproteinase genes. The ADAM21-deficient mice contain a Lac-z gene 
insertion within the metalloproteinase domain with a potential metalloproteinase-dead 
read-through to the end of the gene. This suggests that the regulation of the other 
genes is normally through the metalloproteinase domain possibly by its sheddase 
activity to release growth factors or other cleavage-dependent proteins. Moreover, 
ADAM21 does not have sequences in its C-terminus that are known to allow binding of 
intracellular signaling molecules. The absence of ADAM21 after spinal cord injury 
caused a dramatic decrease in TNFa gene expression levels possibly because of its 
normal sheddase activity on CD14 and/or Notch. CD14, expressed mainly on 
macrophages, co-signals through TLR leading to an increase in Notch and NF-KB 
(Beutler, 2000, Monsalve et aL, 2009). In addition to TNFa expression, the Notch 
signaling pathway has been linked to ADAM 12 expression (Li et al., 2011) and indirectly 
linked to the expression of ADAM8, ADAM33, and MMP12 through increases in 
downstream targets of Notch such as IL-4 and AP-1 (King et aL, 2004, Samuel et aL, 
2005, Tanaka et aL, 2006, Jie et aL, 2009). The decrease seen in ADAM8 in the 
absence of ADAM21 was not decreased to the same degree as that of the other genes 
in the inflammatory cluster. This could be the result of TNFa induced up regulation in 
ADAM8 (Bartsch et aL, 2010). ADAM8 then cleaves TNFaR1 which can then bind 
soluble TNFa, thereby desensitizing a cell to the action of TNFa, and causing an 
apparent feedback loop (Schlomann et aL, 2000, Bartsch et aL, 2010). 
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Of note was the finding that ADAM21 deletion did not affect expression of the 
ADAMTS family members, except for ADAMTS19, following spinal cord injury. The 
expression levels of some ADAMTSs have been shown to be regulated by induction by 
IL-1 or down regulation by hypermethylation (Kuno et aI., 1997, Wagstaff et aI., 2011). 
Our unpublished data (Chapter 3) suggest that ADAM21 in the injured spinal cord is 
located in cells resembling microglia at the injury site. Astrocytes and microglia are 
known to be rapid responders to spinal cord injury and to be intricately involved in 
initiating inflammation (Brambilla et aI., 2005, Kigerl et aI., 2009, Loane and Byrnes, 
2010, Pineau et aI., 2010). Thus, astrocytic and microglial ADAM21 is the most likely 
candidate for playing a central orchestrating role in the secondary responses to injury. 
As with other ADAMs which have enzymatic, adhesive and other signaling properties, 
the physiological targets and mechanism of action of ADAM21 remains to be 
determined. 
We did not observe significant differences in the locomotor function of the 
ADAM21-deficient mice compared to their wild-type littermates despite the major 
differences in levels of inflammatory gene expression. A contusive spinal cord injury 
quickly evolves and progresses into a secondary injury due to inflammation, degradation 
of both blood vessels and axons and ultimately leading to increased cell death (Hall and 
Springer, 2004, Hagg and Oudega, 2006, Bramlett and Dietrich, 2007, Fassbender et 
aI., 2011 b). The extent of inflammation is thought to predict the functional outcomes and 
experimental anti-inflammatory treatments are beneficial (Popovich et aI., 1999, Weaver 
et aI., 2005, Gonzalez et aI., 2007). On the other hand, certain aspects of acute 
inflammation are thought to be beneficial (Barrette et aI., 2007, Kigerl et aI., 2009). For 
example, macrophages remove toxic debris from the injured spinal cord (Popovich and 
Jones, 2003). The role of the individual ADAMs has been proposed to be both beneficial 
and detrimental (Yong, 2005, Rivera et aI., 2010). For example, although ADAM10 and 
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ADAM 17 promote pro-inflammatory signaling events (including TNFo shedding), they 
also have protective effects in the injured nervous system (including shedding of amyloid 
precursor protein, N-cadherin, and Ephrins) (Pruessmeyer and Ludwig, 2009). Further 
research into the effects ADAM21 has on regulating other proteins involved in 
inflammation following a spinal cord injury could elucidate the differential processes 
involved in the inflammatory response. 
In the current study no apparent phenotype was seen in the na"ive (see also 
http://www.informatics.jax.org/external/ko/deltagen/142.html) or injured ADAM21-
deficient mouse, raising the possibility that one of the other metalloproteinases had 
compensated for the lack of ADAM21. In sham animals, there were only two genes with 
significant increases in mRNA levels. ADAM28 was only detected in ADAM21-deficient 
mice under normal or injury conditions, but only in a subset of mice. The presence or 
absence of ADAM28 did not predict the expression levels of the genes regulated by the 
absence of ADAM21. This suggests that ADAM28 had not compensated for the lack of 
ADAM21. ADAMTS16 showed an increase (70%) in ADAM21-deficient mice under 
sham conditions. It has been linked to a decrease in cell proliferation and migration 
when overexpressed in chondrocyte cell lines (Surridge et aI., 2009). After spinal cord 
injury, ADAMTS16 was not changed in wild-type mice but was reduced to 63% (p<0.05, 
Table 5) in the ADAM21-deficient mice. This suggests that ADAMTS16 did not 
compensate under injury conditions, which leads us to believe that under normal 
conditions, it did not compensate in the absence of ADAM21. 
In the wild-type mouse, most of the changes following spinal cord injury involved 
an increase in expression, suggesting that the metalloproteinases play an important role 
in the responses to injury. Our results are similar to the Affymetrix Mouse Genome 430 
2.0 Array data from injured wild-type C57BL6 mice (GEO Profiles accession GDS2159). 
For example, ADAM8, ADAM12, ADAM33, MMP12, which we showed all have an 
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increased expression of more than 10 fold, was 11,163, 435, 298, respectively. Our 
results also confirm reported increases in ADAM8 (Mahoney et aI., 2009), MMP2 
(Goussev et aI., 2003), MMP10, MMP11, MMP12 and MMP13 (Wells et aI., 2003), and 
MMP14 (Mahoney et aI., 2009). There are some differences in changes of 6 genes, 
such as MMP3 and MMP8, at 7 days compared to with the other TaqMan microarray 
analysis 5 days post-injury (Wells et aI., 2003) most likely because of the different type 
of injury. ADAM10 and ADAM17, both associated with sheddase activity on substrates 
such as amyloid precursor protein, Notch, and TNFa in the brain (Asai et aI., 2003, 
Pruessmeyer and Ludwig, 2009), increased by around 2-fold after spinal cord injury 
suggesting that they may play similar roles under that pathological condition. 
Of particular note, MMP10 expression was "turned on" at 7 and 14 days post 
injury. MMP10, also known as Stromelysin-2 or SL-2, has been associated with cell 
migration (Pilcher et aI., 1999, Krampert et aI., 2004). In spinal cord injury, MMP10, like 
ADAM8, seems to playa role in angiogenesis (Heo et aI., 2010). Here, MMP27 was 
another newly expressed gene after spinal cord injury. To date, not much is known 
about MMP27 other than expression profiles (Bernal et aI., 2005). We suggest that 
MMP10 and MMP27 warrant further study as to their role after spinal cord injury. 
Despite the many members, most metalloproteinases were expressed at some point 
before or following spinal cord injury suggesting that this is a very important class of 
proteins in neural injury. 
We also measured the expression of the TIMPs which are natural 
metalloproteinase inhibitors (Brew and Nagase, 2010). The main response was in 
TIMP1, showing an almost 20 fold increase following spinal cord injury in wild type mice. 
This increase would predominantly counteract MMPs (Brew and Nagase, 2010). TIMP1 
has a more restricted inhibitory range than the other 3 TIMPs, showing low affinity for 
MT-MMPs, MMP14, MMP16, MMP19, and MMP24, and is present in plastic regions of 
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the adult eNS (Rivera et aL, 1997, Fager and Jaworski, 2000, Hornebeck et aL, 2005, 
Nagase and Murphy, 2008). However, TIMP-1 has stronger affinity for MMP3 and 
MMP7 than other TIMPs (Hamze et aL, 2007). Thus, it could play similar roles in the 
injured spinal cord. The TIMP1 levels were also increased in the injured ADAM21-
deficient mice although at only 60-70% of wild type. How this would affect the activity of 
the metalloproteinases to affect differential function in the ADAM21-deficient mice 
remains to be determined. The increase in TIMP1 expression seen in the present study 
seems to correlate to its proposed involvement in glial scar formation (Ahmed et aL, 
2005). However, TIMP1 may also act through a mechanism independent of 
metalloproteinase inhibition (Ogier et aL, 2005, Ogier et aL, 2006). TIMP2 was 
increased more in the injured ADAM21-deficient mice than in the wild type mice. In 
humans, TIMP2 has inhibitory actions on all MMPs and ADAM12 (Jacobsen et aL, 2008, 
Brew and Nagase, 2010). TIMP3 is generally thought of as an ADAM and ADAMTS 
inhibitor in addition to its inhibition of MMPs (Amour et aL, 2000, Hashimoto et aL, 2001, 
Kashiwagi et aI., 2001, Wang et aL, 2006, Wisniewska et aL, 2008). 
In conclusion, our data suggest that ADAM21 plays significant role in regulating 
expression of other metalloproteinases perhaps in a nodal manner, as ADAM21 appears 
to be an important regulator of a cluster of genes associated with the immune response 
to injury. Our comprehensive quantitative gene analyses also provide a platform for 




Ref Seq # 
Assa~ID 
ADAM1a Mm02581738 s 1 NM 172126 
ADAM1b Mm00844462 s1 NM 172125 
ADAM2 Mm00802061 m1 NM 009618 
ADAM3 Mm00456453 m1 NM 009619 
ADAM4 Mm00550163 s1 NM 009620 
ADAM4b MmO 1302735 s 1 NM 001038995 
ADAM5 Mm00801437 m1 NM 007401 
ADAM6aJADAM6b Mm00558079_s1 NM _17 4885/NM _ 001009545 
ADAM7 Mm00475743 m1 NM 007402 
ADAM8 Mm00545745 m1 NM 007403 
ADAM9 Mm00475763 m1 NM 007404 
ADAM10 Mm00545742 m1 NM 007399 
ADAM11 Mm00477288 m1 NM 009613 
ADAM12 Mm00475719 m1 NM 007400 
ADAM15 Mm00477318 m1 NM 009614 
ADAM17 Mm01231071 m1 NM 009615 
ADAM18 Mm00438562 m1 NM 010084 
ADAM19 Mm00477337 m1 NM 009616 
ADAM21 Mm01309314 m1 NM 020330 
ADAM22 Mm01316488 m1 NM 001007220 
ADAM23 Mm00478613 m1 NM 011780 
ADAM24 Mm00438567 s1 NM 010086 
ADAM25 Mm00785241 s1 NM 011781 
ADAM26a Mm00783690 s1 NM 010085 
ADAM26b Mm01609627 m1 NM 001009547 
ADAM28 Mm00456637 m1 NM 183366 
ADAM29 Mm01353952_s1 NM 175939 
ADAM30 Mm00810549 s 1 NM 027665 
ADAM32 Mm00462905 m1 NM 153397 
ADAM33 Mm00459691 m1 NM 033615 
ADAM34 Mm01545315 m1 NM 145745 
ADAM36 Mm03015167 s1 NM 001025240 
ADAM38 Mm02342382 s1 NM 001009548 
Table 4. Genes analyzed. 
Assay and reference sequence numbers for all the genes that were analyzed by in the 
Applied Biosystems microfluidic gene Taqman array plates. * = assays that were used 
in an additional analysis which were performed in triplicate with GAPDH as the reference 




Ref Seq # 
Assa~ID 
ADAM39 Mm02581333 s 1 NM_001025380 
ADAMDEC1 Mm00546409 m1 NM 021475 
ADAMTS1 Mm00477355 m1 NM_009621 
ADAMTS2 Mm00805171 m1 NM 175643 
ADAMTS3 Mm00625880 m1 NM_001081401 
ADAMTS4 Mm00556068 m1 NM 172845 
ADAMTS5 Mm00478620 m1 NM 011782 
ADAMTS6 Mm00615566 m1 NM_001081020 
ADAMTS7 Mm01239067 m1 NM_001003911 
ADAMTS8 Mm00479220 m1 NM_013906 
ADAMTS9 Mm00614433 m1 NM 175314 
ADAMTS10 Mm00553926 m1 NM 172619 
ADAMTS12 Mm00615603 m1 NM_175501 
ADAMTS13 Mm01218030_g1 NM_001001322 
ADAMTS14 Mm01169235 m1 NM_001081127 
ADAMTS15 Mm01176187 m1 NM_001024139 
ADAMTS16 Mm00468144 m1 NM_172053 
ADAMTS17 Mm01318698 m1 NM _ 001033877 
ADAMTS18 Mm00552621 m1 NM 172466 
ADAMTS19 Mm00558559 m1 NM_175506 
ADAMTS20 Mm00724059 m1 NM_177431 
ADAMTSL1 Mm00553186 m1 NM_172542 
ADAMTSL2 Mm01326794 m1 NM_029981 
ADAMTSL3 Mm01312414 m1 XM 194370 
ADAMTSL4 Mm00523242 m1 NM 144899 
ADAMTSL5 Mm00481701 m1 NM_025629 
MMP1a Mm00473485 m1 NM 032006 
MMP1b Mm00473493-1J1 NM_032007 
MMP2 Mm00439505 m1 NM_008610 
MMP3 Mm00440295 m1 NM_010809 
MMP7 Mm00487724 m1 NM_010810 
MMP8 Mm00772335 m1 NM_008611 
MMP9 Mm00600164 ..91 NM 013599 






MMP10 Mm01168399 m1 NM 019471 
MMP11 Mm00485048 m1 NM_008606 
MMP12 Mm00500554 m1 NM_008605 
MMP13 Mm01168713 m1 NM_008607 
MMP14 Mm01318966 m1 NM_008608 
MMP15 Mm00485062 m1 NM 008609 
MMP16 Mm00490659 m1 NM 019724 
MMP17 Mm00449292 m1 NM_011846 
MMP19 Mm00491300 m1 NM 021412 
MMP20 Mm00600244 m1 NM 013903 
MMP21 Mm00461814 m1 NM_152944 
MMP23 Mm00488768 m1 NM_011985 
MMP24 Mm00487721 m1 NM_010808 
MMP25 Mm01309189 m1 NM _001033339 
MMP27 Mm01169173 m1 NM_ 001030289 
MMP28 Mm00712992 m1 NM 172797 
TIMP1 Mm00441818 m1 NM_011593 
TIMP2 Mm00441825 m1 NM_011594 
TIMP3 Mm00441827 m1 NM_011595 
TIMP4 Mm00446568 m1 NM_080639 
5erpina1 E Mm00833655 _m1 NM_009247 
5nca Mm01188700 m1 NM_001042451 
F2R Mm00438851 m1 NM_010169.3 
A2m Mm00558642 m1 NM 175628 
TNFa Mm00443258 m1 NM 013693.2 
185 H599999901 51 X03205.1 
Gusb Mm00446953 m1 NM_010368 
Hprt1 Mm00446968 m1 NM_013556 
GapDH Mm99999915 _91 NM_008084 
CNTF H500173456 m1 NM_000614.3 
ADAM9* Mm00475761 m1 NM 007404 
ADAM21* Mm00480375 51 NM 020330 
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Figure 9_ Gene profile of aI/ genes that evoked a consistent signal among the samples 
fol/owing a T9 contusive spinal cord injury. 
Each graph displays the changes in gene expression in wildtype (WT) or ADAM21-
deficient (KO) after injury at 7 and 14 days. In addition, the black triangle signifies the 
ratio in gene expression between the ADAM21 -deficient and the wildtype mice in the 
absence of an injury. All values shown are average fold change ± SEM. n= 8, 8, and 7 
for ADAM21-deficient sham, 7 days, and 14 days post injury, respectively and n= 6, 4, 
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Table 5. Fold changes and p-values of the data in Figure 9. 
KO 7 day vs KO 14 day vs 
























-0.35 NA -0.24 
0.04 NA 0.23 NA 
0.13 NA -1.47 NA 
-0.30 NA -0.22 NA 
0.13 -0.16 NA 
-0.10 -0.32 NA 
0.40 0.29 
-0.53 -0.16 NS 
-0.69 NA -0.03 NA 
0.05 NA 0.26 NA 
NO NO NO NO 













NO NO NO NO 
NO NO NO NO 
0.23 NA -0.11 NA 
~.010 
NO NO NO NO 
NO NO NO NO 
NO NO NO NO 
NO NO NO NO 
NO NO NO NO 
Genes are grouped in numerical order by different subfamilies of metalloproteinases, 
metalloproteinase inhibitors, metalloproteinase substrates, housekeeping/reference 
genes and the negative control , human CNTF. Increases greater than 2-fold are 
highlighted in yellow, decreases greater than 2-fold are highlighted in red and statistically 
significant p-values (less than 0.05) are highlighted in green. Significance was 
determined by changes with a p < 0.05 calculated by an unpaired Student's t-test. n= 8, 
8, and 7 for AOAM21-deficient sham, 7 days, and 14 days post injury, respectively and 
n= 6, 4, and 7 for wildtype sham, 7 days, and 14 days post injury, respectively. Asterisks 
= genes that had expression in only a few samples. NO = Not detectable, NA = Not 



















































































Table 5 Continued 
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Figure 10. Locomotor function in wi/dtype and ADAM21-deficient mice did not differ 
before or after spinal cord injury. 
The BMS scores were not significantly different between genotypes at baseline or after 
injury. As expected at 7 and 14 days post-injury the BMS scores are decreased 





Summary of findings in Chapter 2 
In Chapter 2, we examined the possibility that stimulation of the 5HT1A 
receptor causes a decrease in cAMP resulting in an increase in CNTF leading to 
an increase in neurogenesis as seen with stimulation of the 02 receptor (Yang et 
aI., 2008). As shown by others, we saw an induction of neurogenesis in the SGZ 
of rats after stimulation of the 5HT1A receptor by the known agonist, 8-0H-OPAT 
(Banasr et aI., 2004, Huang and Herbert, 2005, Soumier et aI., 2010). However, 
we found that unlike the 02 receptor, neurogenesis in the rat SGZ is not 
mediated by CNTF. In addition, stimulation of the 5HT1A receptor via 
intraperitoneal injection of 8-0H-OPAT does not induce neurogenesis in the SVZ 
and SGZ of mice or the SVZ of mice or rats. Therefore, 5HT1A receptor 
stimulation results in an increase in neurogenesis in the hippocampal formation 
of rats at dose of 1 mg/kg/day, which is not mediated by CNTF. 
8-0H-DPAT does not increase neurogenesis in the naiVe mice 
The initiation of the study in Chapter 2 was due in part to the Santarelli 
(2003) paper, which showed increased neurogenesis in the SGZ of 129Sv/Ev 
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mice after treatment with 8-0H-OPAT, a 5HT1A agonist, which was diminished in 
the 5HT1A receptor knockout mice (Santarelli et aI., 2003). Due to the lack of 
neurogenic response in the 5HT1A knockout mice, the 5HT1A receptor seemed 
to be solely responsible for the induction of neurogenesis by 8-0H-OPAT in the 
SGZ. However, we were not able to replicate the data showing neurogenesis in 
the SGZ of 129Sv/Ev mice following 5HT1A receptor stimulation by 8-0H-OPAT 
(Santarelli et aI., 2003). In our laboratory, we observed no change in 
neurogenesis in the SVZ or SGZ after administration of (R)-(+)-8-0H-OPAT in 
either C57BLl6J or 129Sv/Ev mice either acutely (3 days) or chronically (28 
days). 
So why would we not see increased neurogenesis after administration of 
the 5HT1A agonist, 8-0H-OPAT, in mice when the neurogenic response of 8-
OH-OPAT was seen in wildtype mice and abolished in the 5HT1A knockouts? 
There could be a couple of possible reasons for the discrepancy in neurogenic 
effects of 8-0H-OPAT between our studies. First, the Santarelli (2003) paper 
had used the racemic mixture while we used (R)-(+)-8-0H-OPAT. In humans, 
(S)-(-)-8-0H-OPAT binding affinity is similar to that of (R)-(+)-8-0H-OPAT; 
however, it is approximately 50% less efficacious or potent than (R)-(+)-8-0H-
OPAT on the 5HT1A receptor (Cornfield et aI., 1991, Yoshitake and Kehr, 2004). 
This would mean that although the two enantiomers bind equally to the receptor, 
in the racemic mixture half of the bound receptors produced only 50% activity to 
the stimuli resulting in 25% less intrinsic activity than the R-enantiomer alone. 
Furthermore, in rats, the racemic mixture is 2-fold less potent than the R-
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enantiomer at reducing dorsal raphe nucleus firing acutely (5 minutes following 
injection) (Lejeune et aI., 1997). Presumably, this would also mean that the 
racemic mixture could have a 2-fold decrease in the negative feedback produced 
by the autoreceptors. However, it is unlikely that this is the reason for the 
discrepancy between our two studies. 
A second and more likely explanation for the discrepancy could be due to 
the behavioral/stress tests performed on in the Santarelli paper. Their goal was 
to examine the effects of 5HT1A receptor on depression. Therefore, they were 
not working on na·ive mice, but stressed mice. Stress has been shown to affect 
production and survival of new neurons (Schoenfeld and Gould, 2011). The 
behavioral analysis used in the Santarelli paper includes unpredictable stressor 
test, novelty-suppressed feeding test, and cue fear test. Additionally, the 
unpredictable stressor test involved changing the environment surrounding the 
mice by altering the sawdust bedding, cage tilting, predator sounds, and 
modifying to the light cycle. Our studies did not contain any behavior/stress 
testing. Additionally, personal correspondence with Benjamin Samuels from 
Rene Hen's group, suggested that the increased stress from the behavioral tests 
might have lowered the baseline level of neurogenesis in controls. Therefore, 8-
OH-DPAT stimulation of the 5HT1A receptor could be involved in the restoration 
of neurogenesis to basal levels or prevented the decrease in neurogenesis since 
behavior testing occurred after administration of 8-0H-DPAT. 
Although it is plausible that either the racemic mixture and/or the behavior 
testing caused the discrepancy in between the studies in Rene Hen's lab and our 
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lab, the discrepancy in neurogenic responses is most likely due to the stress-
induced decrease in basal level of neurogenesis observed in the Santarelli 
paper. In order to prove this hypothesis, we could look at changes in 
neurogenesis triggered by stress from behavioral analysis like what was done in 
the Santarelli paper. This could be accomplished using four experimental 
groups. The first two groups would not have any behavior testing and would be 
administered either saline or 8-0H-DPAT over 4 weeks. The next two groups 
would be subjected to behavior tests that cause behavioral/stress tests that 
mimic depression in mice with one group receiving saline and the other receiving 
8-0H-DPAT. By analyzing the changes in neurogenesis in each of these groups, 
we could determine whether 8-0H-DPAT prevents decreases in neurogenesis 
caused by conditions that are thought to mimic depression. In addition, if 8-0H-
DPAT would be given following the induction of depreSSion like behavior in mice, 
this would determine if 8-0H-DPAT is protective against reduction in 
neurogenesis or can be an anti-depressant by increasing neurogenesis. If 8-0H-
DPAT were found only to prevent the decline in neurogenesis as a result of 
depression instead of increaSing neurogenesis, this would suggest that although 
depression decreases neurogenesis, the antidepressant activity is not related to 
neurogenesis. This would not be useful in humans as pretreatment for 
depression and would only be applicable in people with recurrent depression. 
Conversely, if 8-0H-DPAT does indeed increase neurogenesis back to basal 
level, it would suggest that neurogenesis plays a role in recovery from 
depression. In humans, this would mean that further investigation into drugs that 
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would increase neurogenesis could be useful in the treatment of depression. 
Therefore it is important to investigate which mechanism is correct for 5HT1A 
receptor stimulation so this knowledge can be used to treat depression in human. 
Region-selective difference of 8-0H-DPAT effects on neurogenesis in Sprague 
Dawley rats 
Neurogenesis in the SGZ of rats after stimulation of the 5HT1A receptor 
with the racemic mixture of 8-0H-DPAT has been established previously (Banasr 
et aL, 2004, Huang and Herbert, 2005, Soumier et aL, 2010). Therefore, we 
wanted to test (R)-(+)-8-0H-DPAT in rats as a positive control for bioactivity. 
Within seconds of drug administration the typical serotonergic behavior of 
weaving head, flat body posture and forepaw treading (Tricklebank et aL, 1985) 
was observed in the rats which contrasts to the lack of physical response seen in 
mice after 8-0H-DPAT administration. In addition, neurogenesis in the SGZ was 
significantly increased after only 3 days of 8-0H-DPAT treatment. This 
confirmed that our drug was indeed active and induced neurogenesis in 
response to drug treatment that we were able to quantify using unbiased 
stereology. However, we did not see any neurogenesis in the SVZ as had been 
reported previously at 4 hours after 8-0H-DPAT treatment (Banasr et aL, 2004). 
After personal communication with Dr. Annie Daszuta, we found several possible 
explanations for the discrepancy in our findings. These differences include 
differences in strain, drug, and quantification of neurogenesis. In the Banasr 
(2004) paper, they had used the adult Wistar rat and racemic (±)-8-0H-DPAT. 
88 
The differences between the racemic mixture and R-enantiomer were discussed 
earlier in Chapter 5. Surprisingly, the quantification for cell proliferation in all 
other regions discussed in the Banasr paper was by unbiased stereology with the 
exception of in the SVZ where total number of BrdU cells was reported per SVZ 
per section with a total of 5 sections counted per animal. Since we used 
stereology, a more accurate quantification of neurogenesis, this could be a major 
area for discrepancy and might suggest that their conclusion with regards to the 
SVZ was incorrect. 
Stereology was designed to estimate, for example, the total number of 
cells in an anatomically defined area. The balance is in having the appropriate 
sampling of a region to encompass an accurate sample of biological variation. 
Under sampling and/or oversampling can result in an inaccurate portrayal of the 
total number of cells across a region. Therefore, counting every cell present in a 
section and averaging the total number of cells per section might be a precise 
method, but it is unlikely that it is accurate due to the absence of estimation in the 
third dimension. This is due to the inherent biological variation in that cells are 
not generally evenly distributed in all three axes or even in the same manner 
across animals; therefore, by sampling in the middle of an anatomical region 
leads potentially to over estimation and a slight shift toward the edge of the 
region could cause under estimation. Thus, in addition to systematic sampling 
across the entire area of tissue, the equation used in the total estimation across 
the anatomical region takes into account the sampling frequency and tissue 
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sampling fraction which minimize the biological variation in order to quantitatively 
and accurately estimate the number of cells in the region of tissue analyzed. 
Lastly, at 4 hours there would be an acute response to the 5HT1A agonist 
to the local 5HT1A receptors, presynaptic receptors located on astroglial cells, in 
the SVZ resulting in an increase in neurogenesis (Banasr et aI., 2004). However, 
it is possible that by 3 days the 5HT1A autoreceptors, presynaptic receptors on 
the projections from the raphe nucleus, have been up regulated in response to 
drug administration and their inhibitory function is predominating in the SVZ 
(Kinney et aI., 2000). Additionally, the regulation of 5HT1A signaling in the 
hippocampal formation is not affected by the autoreceptor which also explains 
are response to 8-0H-OPAT in the SGZ but not in the SVZ (Riad et aI., 2001, 
Banasr et aI., 2004). Therefore, we conclude that 5HT1A receptor stimulation 
can induce neurogenesis in the SGZ, but not in the SVZ at 3 days in rats. In 
order to circumvent the negative feedback in the SVZ, lowering the dose or 
giving intermittent treatment could potential result in decrease in the negative 
feedback. However, the most effective way would be to give pindolol, a 
nonselective beta-blocker and partial beta-adrenergic receptor agonist, to 
augment the effectiveness of 5HT1A agonist treatment (Kinney et aI., 2000). 
Although the mechanism of action of pindolol's augmentation of SSRls and 
5HT1A agonists is still in question, it has been shown clinically to bypass the 
need for desensitization of the autoreceptors resulting in an almost immediate 
clinical effect as contrasting the delayed effectiveness normally seen with SSRI 
drug regimens (Kinney et aI., 2000). 
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It seems that in rats at least there is region specificity. Although humans 
are reported to have neurogenesis in the hippocampal formation, it is difficult to 
conclude the possible outcome for humans in light of the species differences 
seen between mice and rats. It goes back to the age old question as to which 
more closely resembles what occurs in humans. In order to get closer to an 
answer for whether 5HT1A induced hippocampal neurogenesis is present in 
humans, the next step would be to look at 5HT1A agonists in higher mammals or 
move directly to non-human primates which would more accurately predict the 
likelihood of effects on neurogenesis in humans. If region specificity is also 
found in non-human primates and used to infer the actions of 5HT1A agonists in 
human, this would limit treatment to diseases with neuronal loss in the 
hippocampal formation such as Alzheimer's disease since there is loss of 
neurons in the hippocampal formation among other regions of the brain. 
Therefore, treatment of a 5HT1A agonist might improve memory and learning 
and decrease aggression in Alzheimer's patients if 5HT1A can elicit a neurogenic 
response in the hippocampus (Lai et aI., 2003) . 
Although we were not able to increase neurogenesis in the SVZ, the most 
active proliferative region of the brain, it is a very important target and potentially 
the most effective region to study for neuron replacement. This is due to the 
endogenous activity already present in the SVZ such as the ability for new 
neurons to migrate great distances under normal circumstances. In order to 
develop neuron replacement therapies, continuation of studies which investigate 
possible pathways that can be exploited in order to manipulate and/or augment 
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neurogenesis in the SVZ is essential. Under the right circumstances, some 
diseases states could benefit from increasing neurogenesis in the SVZ such as 
stroke, Huntington's, epilepsy, and aging (Curtis et aI., 2007a). Furthermore, it is 
important to investigate and understand the differences of these two regions of 
the brain such as endogenous regulation by receptors that either stimulate or 
inhibit neurogenesis and what types of cells are produced in each region. As 
more information is attained on the regulation of neurogenesis, we can apply it to 
humans in an effort to control the migration and integration of these new neurons 
to better rescue the damage or non-functioning portions of the brain in 
neurodegenerative disease. 
5HT1A receptors and depression 
The 5HT1A autoreceptors are not present in the hippocampal region while 
the SVZ is under constant regulation by these autoreceptor unless 
desensitization occurs. However, the hippocampal formation is under the control 
of the 5HT1 S autoreceptor (Malagie et aI., 2001). The 5HT1A receptor function 
and regulation seem to vary depending on the region of interest (Riad et aI., 
2001) which is probably due to the density and localization of the 5HT1 A 
receptors. It is hypothesized that the variability in patient responses including 
delay in onset of therapeutic effect to the treatment with selective serotonin 
reuptake inhibitors in depression is due to the negative feedback of 
autoreceptors (Slier et aI., 1998). In a recent study, animals with low and high 
amounts of 5HT1A autoreceptors were found to respond differently to stress 
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(Richardson-Jones et aI., 2010). The lower the amounts of autoreceptors 
present gave better serotonergic tone and responded better to stressors and 
SSRI treatment (Richardson-Jones et aI., 2010). Thus, the level of autoreceptors 
present could be the main cause of the vast degree of variability in the 
effectiveness with anti-depressants drug regimens. Pindolol, primarily known for 
being a non-selective beta blocker, is thought to accelerate the therapeutic effect 
of antidepressant therapies by inhibition of autoreceptors which reduce firing of 
serotonergic neurons resulting in potentiation of the effects of SSRI treatment by 
increasing the serotonergic tone of the system (Berney et aI., 2008). 
Furthermore, return of autoreceptor function could also explain the development 
of resistance after chronic administration of antidepressants. 
In general, the depression field has ignored the presence of 5HT1A 
receptors on astrocytes and focused on neuronal 5HT1A receptors. Although 
5HT1A receptors are in high abundance on glial cells (Whitaker-Azmitia et aI., 
1993), most effects of serotonin are assumed to be as a result of stimulation of 
neuronal 5HT1A. In addition, serotonin autoreceptors have attracted attention 
over the last decade because of the inhibitory effects on the serotonin pathway 
and resulting delay in the therapeutic effect of antidepressants such as SSRls. 
The reason for ignoring the glial component of the serotonergic system is 
unclear. However, astrocytes provide support for neurons though release of 
neurotrophic factors, cytokines, and calcium flux. Therefore, astrocytes should 
be considered part of the neuronal network. In neurodegenerative diseases, the 
neurons are dead, dying, or not functioning properly and astrocytes are relatively 
93 
unaffected. This puts astrocytes in an advantageous position of being available 
and accessible as a tool to promote neurogenesis. 
Caveats and future directions for further investigation in neurogenesis 
As mentioned earlier in this chapter, stimulation of 5HT1A receptor might 
be protective in stress-induced decreases in neurogenesis. In order to 
investigate this further, we could use 5HT1A agonist, 8-0H-OPAT, and 
antagonist, WAY100135 or (-)-tertatolol (another beta-blocker with 5HT1A 
inhibitory activity), to look at the potential for 5HT1A receptor increases in 
neurogenesis after a perturbation of the system like a stroke. Strokes located in 
different areas of the brain could provide an opportunity to look at regional 
differences of 5HT1 A. The murine 5HT1 A receptor might not playa role in 
regulating neurogenesis under normal circumstances, but potentially could be 
inducible following an insult. However, the drug administration would need to 
follow the insult/injury to be clinically relevant which contrasts with the Santarelli 
paper where 8-0H-OPAT was given prior to induction of stress. Therefore, it is 
possible that 8-0H-OPAT is required to be present before the insult. However, it 
could be possible for 5HT1A stimulation following the insult could still result in 
protection from subsequent neuronal loss or decreases in neurogenesis. 
Additionally, in our hands, a decrease in nNOS seemed to predict 
neurogenesis. In fact, nNOS might be a better target for increasing 
neurogenesis by using an inhibitor such as L-NAME which has been shown to 
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increase neurogenesis in the SVZ of mice (Romero-Grimaldi et aI., 2008). L-
NAME is a competitive inhibitor of NOS, but unfortunately lacks specificity 
between iNOS, nNOS, and eNOS. The lack of specificity comes with a multitude 
of side effects such as impairment of memory retrieval/acquisition and blockade 
of non-noradrenergic, non-cholinergic nerves leading to erectile dysfunction and 
impaired bowel motility (Moore and Handy, 1997). While these side effects do 
not preclude the need for further study, they would decrease patient compliance 
and potentially prevent FDA approval with a non-specific NOS inhibitor. 
Therefore, further study into other receptors that could inhibit nNOS or more 
selective nNOS inhibitors would be useful to study in an effort to find additional 
drugs that could be used in conjunction with a D2 agonist to promote increases in 
neurogenesis and prevent systemic side effects. 
Due to the degree of complexity of the 5HT1A pathway, glial 5HT1A 
responses are difficult to tease out of the responses seen with 5HT1A agonist. It 
seems likely that the lack of neurogenic effects in the SVZ after 8-0H-DPAT 
systemic administration could be attributable to inhibition by 5HT1A 
autoreceptors. This could be confirmed by knocking out the autoreceptors by 
de nervation of the raphe nuclei using the serotonergic neurotoxin, 5,7-
dihydroxytryptamine which alone has been shown to increase neurogenesis. In 
addition by varying the degree of denervation, one could potentially see a dose 
dependent increase in neurogenesis. In our studies, we saw a region and 
species specificity to the activity in response to the 5HT1A agonist, 8-0H-DPAT. 
There are also marked differences in the responses between mice and rats 
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which were described in Chapter 2. Therefore, further research is needed in 
order to tease out the specific mechanism of action of the 5HT1A receptor in 
specific regions of the brain. However, one must question the validity of studying 
the 5HT1A receptor in rodents when there is such a wide range in responses to 
stimulation. Although the 5HT1A receptor has 89% homology between rats and 
humans and 86% homology between mice and humans, there seems to be 
drastic differences in the function in difference species. The lack of serotonergic 
syndrome in mice given up to 10 times the normal dose of 8-0H-OPAT given to 
rats leads me to believe that the murine 5HT1A receptor does not have the same 
biological function as in humans and rats. Since both rats and humans can 
exhibit serotonergic syndrome in response to serotonin, rats seem to be the 
better choice for further study into the function of the 5HT1 A receptor before 
studying this paradigm in non-human primates or humans. 
What would I have done differently in Chapter 2? 
One of the biggest problems with Chapter 2 is the lack of a biological 
effect in the mouse. In order to understand the activity of 8-0H-OPAT activity in 
the mouse, it would have been nice to have added a couple of experiments that 
looked at the bioactivity of 8-0H-OPAT on mice. First, our hypothesis was that 
the decrease in cAMP following 5HT1A stimulation would cause an increase in 
CNTF. However, we never measured cAMP. If we had measured cAMP levels 
we might have seen, for instance, that there was no change in cAMP. Then we 
could have either adjusted the dosage or found another drug to test for changes 
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in cAMP before doing so much work looking at mRNA and neurogenesis 
analysis. In addition, mild hypothermia was reported in mice following treatment 
with 8-0H-DPAT. It would have been relatively simple to test the temperature of 
the animals periodically throughout the study for changes in the basal body 
temperature. A change would indicate bioactivity. Lastly, I could have added 
another experimental group that combined 8-0H-DPAT with a 5HT1A antagonist 
to determine if the auto receptors were causing the lack of effect in mice. 
Summary of findings from Chapter 3 and 4 
In Chapter 3 we found that the absence of ADAM21 protein did not result 
in a function phenotype measured by two locomotors tests, BMS and beam walk, 
and two thermal nociception tests, Hargreaves and tail flick. Histologically, we 
found no significant difference between genotypes in spared white matter, GFAP 
immunostaining, or CGRP immunostaining. The neutral phenotype was thought 
to be a result of compensation by another zinc metalloproteinase; however, we 
found no evidence of compensation on the mRNA level for the absence of 
ADAM21. Interestingly, we found a massive decrease in several genes which 
have been associated with inflammation, i.e., ADAM8, ADAM33, MMP12, and 
TNFo. These changes lead us to believe that ADAM21 has a regulatory role in 
the inflammatory gene response following spinal cord injury. Thus far, these 
changes in mRNA have not given a functional phenotype, but become the basis 
for further research into the role of ADAM21. 
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Hypothesis for potential role of ADAM21 in pain development following spinal 
cord injury 
As mentioned in Chapter 3 and 4, robust ADAM21 immunostaining was 
found in highly plastic areas of the brains (Yang et aI., 2005). In addition, it is 
predicted to have a catalytically active zinc metalloproteinase site which 
pharmacologically makes it a great target for inhibition by a small molecule. Our 
original hypothesis was based off the ADAM21 immunostaining in growing axons 
and presence in radial glial lineage cells. We wanted to investigate the possibility 
that ADAM21 was involved in sprouting after spinal cord injury. Upon 
immunostaining for ADAM21 in the spinal cord it was found to be localized in 
laminae I and II of the dorsal horn and in the ependymal cells surrounding the 
central canal. The staining in the dorsal horn was punctated and occasionally 
resembled fibers. Since nociceptive fibers (C and Ao fibers) correspond to the 
location of ADAM21, we chose to investigate the role of ADAM21 in the pain 
response after spinal cord injury using ADAM21-deficient mice. Conversely, we 
now believe that the ADAM21 immunostaining is an artifact and does not 
resemble the true localization of ADAM21 in the spinal cord due to the lack of co-
labeling of ADAM21 and l3-galactosidase immunostaining. As the basis for our 
original hypothesis turned out to be false, it makes sense that we did not see 
changes in sprouting of CGRP in the dorsal horn or changes in GFAP since this 
is not the region or cell type the ADAM21 protein is located. 
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ADAM21 deletion and spinal cord injury 
A cluster of genes known to be linked with inflammation was greatly 
increased in wildtype, but considerably reduced in their response to injury in the 
ADAM21-deficient mice (i.e., ADAM8, ADAM12, ADAM33, MMP12, and TNFa). 
Increases in inflammation would presumably cause increases in pain and 
decrease in locomotor function. Likewise, decreases in inflammation should 
produce decreases in pain and improved locomotor function, but this was not the 
case with ADAM21 deficient mice. ADAM21 lacked a functionally significant 
difference in pain development after spinal cord injury as we found no changes in 
thermal nociception measured by Hargreaves and tail flick tests following spinal 
cord injury. In addition, ADAM21-deficient mice responded similarly to the spinal 
cord injury as the wildtype littermates in all parameters tested. 
A possible explanation for the absence of a function phenotype is that the 
changes in mRNA as a result of the lack of ADAM21 protein did not translate into 
a reduction in inflammation. Until we are able to look at the immunological 
response in the ADAM21-deficient mice, this conclusion is purely speculative. As 
discussed in Chapter 4, ADAMs and other metalloproteinases have been shown 
to overlapping physiological functions {Horiuchi, 2005 #2187, but there was no 
evidence of compensation by another zinc metalloproteinase. Yet other proteins 
could compensate or regulate the changes resulting from a lack of ADAM21 such 
as TIMPs, a group of endogenous metalloproteinase regulators. Although there 
were changes in 3 of the 4 TIMPs following spinal cord injury, there was not a 
significant difference in the changes in TIMPs between genotypes. The 
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consistent inhibitory tone of the system could account for the lack of a phenotype 
if the changes in metalloprotease were inhibited to the same extent in both 
wildtype and ADAM21-deficient mice. For instance, TIMP1 could mitigate the 
different changes in metalloproteinases resulting in the neutral outcome that was 
observed. In order to confirm this is the case, a double knockout of TIMP1 (or 
other TIMPs) and ADAM21 should be compared. However, combinations of 
small changes in TIMPs and metalloproteinases could account for no lack of 
compensatory mechanism in ADAM21 deficient mice. 
Another possibility is the fact that we are looking at mRNA levels at 7 and 
14 days post injury. It is possible that an increase/decrease in mRNA does not 
translate into an increase/decrease in protein levels/activity. Therefore, the 
changes in mRNA could be transient and any affect as a result of these acute 
changes could be diminished over the 6 weeks. In addition, we only looked at 
these two early time points which could not be giving us a full picture as to what 
is going on in the system. 
Spinal cord injury resulted in numerous changes in metalloproteinase 
activity, but none of these changes resulted in a functional phenotype. Due to 
the complexity of the regulatory mechanisms of metalloproteinases, it is plausible 
that other proteins not included our array could compensate the lack of a 
phenotype such as feedback or feed forward loops like seen with ADAM8, 
TNFa, and TNFR1. In addition, regulation of both beneficial and destructive 
metalloproteinases and/or TIMPs could explain the neutral phenotype. An 
example of this would be the feedback loop of ADAM8 and TNFa that was 
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discussed in Chapter 4 (Bartsch et aI., 2010). Although there is no evidence of 
compensation of ADAM21, the complexity of the regulation of the 
metalloproteinases by not only each other, but also TIMPs and other proteins 
make finding a definitive compensatory mechanism challenging. 
Caveats pertaining to ADAM21-deficient mouse 
During the course of the array portion of the study, it was discovered that 
exon 1 of ADAM21 was not present in the spinal cord. This was not unexpected 
since it was reported that exon 1 of ADAM21 in the testis was only present in 
germ cells (Yi et aI., 2010). After obtaining an assay for exon2, we found 
expression of ADAM21 in both wild type and ADAM21-deficient mice. However, 
under further investigation of the mRNA from ADAM21-deficient mice, we found 
that the insertion site of the LacZ cassette was in the middle of the 
metalloproteinase domain effectively eliminating the potential for 
metalloproteinase activity. We also found that starting at the beginning of the 
disintegrin domain, mRNA transcription resumed to include the rest of the C-
terminal portion of the ADAM21 transcript. Upon further investigate a theoretical 
promoter region followed by a putative start codon was found downstream of the 
metalloproteinase catalytic site. However, this is highly speculative until we are 
able to determine if this truncated transcript is translated into protein. 
Unfortunately, additional ADAM21-deficient mice were not available to confirm 
presence of a truncated ADAM21 protein. Additionally, our antibody for ADAM21 
shows similar immunoreactivity in wildtype and ADAM21-deficient mice. This 
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means either that our antibody is not specific or it is detecting a truncated 
ADAM21 protein. Lastly, ~-galactosidase immunostaining revealed a different 
expression pattern than was seen with the ADAM21 antibody. This probably 
means that the ADAM21 antibody is not specific and would explain why our 
original hypothesis failed-it was based off false information. Therefore, the 
exact type of genetically modified ADAM21 we have obtained is still in question. 
We have two options available: a metalloproteinase-null ADAM21 and the 
function of the other domains remain intact or we could have an ADAM21-
deficient mouse that has truncated ADAM21 mRNA that lacks the ability to be 
translated into protein. We plan to investigate further these two possibilities by 
using another antibody for ADAM21 which recognizes the metalloproteinase 
domain which will be validated by ~-galactosidase immunostaining. If this 
antibody has the same immunostaining as the ~-galactosidase antibody then the 
ADAM21 antibody that targets the C-terminus, PSGPKETKASSPG, is not 
specific to ADAM21. Of note, BLAST analysis of this 13 amino acid sequence 
produced only one exact match, ADAM21, but included partial matches to 140 
other mouse proteins. If, however, the pattern of staining with the new ADAM21 
antibody matches our C-terminus ADAM21 antibody, then there could be some 
alterations in the expression pattern of ~-gal such as different regulation, 
transport, or processing. Lastly, if the truncated protein is present, this would 
suggest that the changes in inflammatory gene were a result of the lack of 
metalloproteinase activity of ADAM21. Whereas, a knockout of the entire protein 
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does not allow one to discern which domain is responsible for the gene changes 
that occurred after spinal cord injury. 
Future directions 
The data from the ADAM21 deficient mice suggests that ADAM21 does 
not playa role in pain development or influence the recovery of locomotor or fine 
motor control following spinal cord injury. In apparent contradiction, ADAM21 
could potentially be involved in the inflammatory response following spinal cord 
injury. Massive changes in metalloproteinases and TNFa point to ADAM21 
having a regulatory role following spinal cord injury. Although there were other 
changes in mRNA levels of other metalloproteinase, the magnitude of change 
seen in this cluster of inflammatory genes points to a more direct relationship 
between them and ADAM21. Further validation is still needed. Validation of 
these results could be accomplished by the following techniques: western blot, 
ELISA, or immunostaining for the genes of interest. In addition, following up with 
the use of CD45 and CD68 immunostaining (microglia and 
monocytes/macrophages, respectively) in the spinal cord tissue of ADAM21-
deficient mice as an indicator of the degree of inflammation would give us a 
better ideas as to the degree of inflammation in these mice compared with 
wildtype littermates. If ADAM21 is indeed a master regulator of inflammation 
following spinal cord injury, this could open up a new avenue for manipulation of 
inflammatory processes by blocking ADAM21 activity with a small molecule could 
potentially provide an avenue for reduction of inflammation. First, the pro-
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inflammatory activity of ADAM21 would need to be narrowed down to the domain 
responsible. Although this would need further investigation to confirm, more than 
likely the metalloproteinase domain is the primary domain responsible for 
changes seen in the inflammatory genes upon deletion of ADAM21. 
Confirmation could be done by point mutations of the catalytic site of ADAM21 
resulting in a metalloproteinase dead protein. 
Although there are metalloproteinase inhibitors, there is not an ADAM21 
metalloproteinase specific inhibitor to date. The use of broad-spectrum 
metalloproteinase inhibitors would inhibit large groups of metalloproteinases and 
is not desirable. However, continued effort has been put into design of inhibitors 
of specific metalloproteinases although selectivity of such an inhibitor is a great 
obstacle due to the high degree of homology of the catalytic site of zinc 
metalloproteinases (Fisher and Mobashery, 2006, Corbitt et aI., 2007, Jacobsen 
et aL, 2010). Non -specific metalloproteinase inhibition results in detrimental side 
effects such as MMP-induced musculoskeletal syndrome which can cause 
muscle stiffness, loss of range of motion in large joints, joint swelling, and soft 
tissue pain as seen in rats (Renkiewicz et aL, 2003) and humans (Coussens et 
aL, 2002, Krzeski et aL, 2007). Therefore, specific inhibitors would reduce side 
effects like those mentioned above. The most successful method for increased 
specificity in the development of metalloproteinases has been accomplished 
using bioinformatics to model the catalytic site. The catalytic site contain 6 
recognition "pockets" around the catalytic zinc and the distance between these 
pockets vary among the different metalloproteinases (Dorman et aL, 2010). By 
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utilizing this difference and the computing power of computers, potential selective 
small molecules can be found and tested for selectivity and bioavailability. 
Alternatively, small peptide based drugs could be designed to bind to more 
specific regions around the catalytic site to block access. 
The question remains whether we could reduce the chronic inflammation 
after spinal cord injury which has been shown to be detrimental consequences in 
the long-term for spinal cord injury patients. A specific inhibitor of ADAM21 
metalloproteinase would have many hurdles to overcome before it could be 
brought to the clinic. Once a suitable candidate is identified, the timing of when 
to begin treatment of the inhibitor and the duration of treatment would need to be 
determined. Some inflammatory processes are beneficial and the exact time 
when beneficial inflammation turns detrimental is still under investigation 
(Popovich and Jones, 2003, Crutcher et aI., 2006, Sandhir et aI., 2011). Is it 
required for the rest of the patient's life to keep the chronic inflammation at bay? 
These question still need to be answered and I believe it is important to work to 
find inhibitors specific to different metalloproteinases than could be used not only 
in spinal cord injury but also asthma, cancer, periodontal disease and many more 
diseases as the metalloproteinases are involved in a vast range of diseases. 
What would I have done differently in the Chapter 3 and 4? 
If I could change the order in which I looked at the role of ADAM21 we 
might have more answers than questions at this point. Initially upon receiving the 
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ADAM21-deficient mice, I should have confirmed by qPCR that ADAM21 mRNA 
was not present. This way I would have been able to figure out whether or not 
the truncated transcript of ADAM21 is translated into a truncated protein or 
degraded. This would have allowed me the time to explore what type of 
genetically modified mouse we had before spending countless hours doing a 
spinal cord injury study which left many more questions than it answered due to 
the current uncertainty of the mouse strain. In the process of investigating this 
mouse strain, I would have run a western to confirm protein sizes and the 
absence or presence of a truncated protein and done ~-galactosidase 
immunostaining from the start to look which cells produced ADAM21. This would 
have led to the inconsistency in the ~-galactosidase and ADAM21 staining. All of 
which could have been confirmed before years of work went in to a mouse that 
mayor may not be a true knockout. Of course looking back, it would have been 
nice to have done the comprehensive array following spinal cord injury prior to 
the 6 week behavior study on pain and plasticity in order to formulate a better 
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